

# Predicting binding free energies: Frontiers and benchmarks (a perpetual review)

David L. Mobley<sup>1,\*</sup> and Michael K. Gilson<sup>2,†</sup>

<sup>1</sup>*Departments of Pharmaceutical Sciences and Chemistry,  
University of California, Irvine, CA, USA, 92697*

<sup>2</sup>*Skaggs School of Pharmacy and Pharmaceutical Sciences,  
University of California, San Diego, CA, USA, 92092*

(Dated: July 4, 2017)

Binding free energy calculations based on molecular simulations provide predicted affinities for biomolecular complexes. These calculations begin with a detailed description of a system, including its chemical composition and the interactions between its components. Simulations of the system are then used to compute thermodynamic information, such as binding affinities. Because of their growing promise for guiding molecular design, these calculations have recently begun to see widespread applications in early stage drug discovery. However, many challenges remain to make them a robust and reliable tool. Here, we highlight key challenges facing these calculations, describe known examples of these challenges, and call for the designation of standard community benchmark test systems that will help the research community generate and evaluate progress. In our view, progress will require careful assessment and evaluation of new methods, force fields, and modeling innovations on well-characterized benchmark systems, and we lay out our vision for how this can be achieved.

**Manuscript version 1.1.4 pre-release.** See <https://github.com/mobleylab/benchmarksets> for all versions.

**Permissions.** Posted with permission from the *Annual Review of Biophysics*, Volume 46 (c) 2017 by Annual Reviews, <http://www.annualreviews.org/>. The right to create derivative works is also executed here with permission from the *Annual Review of Biophysics*.

## TODO LIST

- DLM: This organization is slightly inconsistent with the lysozyme organization, because this starts off with the biological relevance of bro-modomains. I'm wondering if we should move the biology to a separate subsection and just jump in to what's relevant for modeling them? Specifically, the target audience I'm imagining is someone who just wants to benchmark methods and doesn't care about the biology of the system, just what is important for modeling it. Thoughts? PROBABLY that also means you want to lead with a summary of the most modeled binding systems (as in the lysozyme case) and what is known about the challenges there. ..... 16
- DLM: In trying to organize like lysozyme, it seems like discussion of the specific benchmark proposed should get its own subsubsection header, so I proposed adding one above. Thoughts? ..... 17
- DLM: Seems like the below text mostly belongs in the bit on biological background? ..... 17

- DLM: In the sentences just prior, perhaps make it clearer what assertion/what issues. Do you mean something like "However, to serve as a hard benchmark, considerable care needs to be taken when dealing with several sampling challenges," or some such? ..... 17
- DLM: What do you think about making this subsection be "Computational challenges posed by the BRD4(1) benchmarks" and then have the two things below which you currently have as "subsubsections" use a smaller (paragraph?) label instead? This would be more consistent with the lysozyme material. Alternatively, I would also be happy with subsubsections called "BRD4(1) computational challenge: ZA loop flexibility" and "BRD4(1) computational challenge: sidechain sampling" or something similar. My issue is just that right now the organization seems fairly different from lysozyme and it's hard to keep track of what the subsubsection headers are supposed to mean. ..... 17
- DLM: I have some TeX comments suggesting rephrasings in this paragraph ..... 17
- DLM: Some questions in the TeX on what you mean ..... 19

\* [dmobley@mobleylab.org](mailto:dmobley@mobleylab.org)  
† [mgilson@ucsd.edu](mailto:mgilson@ucsd.edu)

- DLM: For consistency with lysozyme organization, you probably want this section to be part of either the intro to bromodomains, or the section discussing sampling problems. For example, see the lysozyme section "The apolar and polar cavities and their ligands". ALSO, don't take a separate paragraph to describe each study. (We initially did that in the lysozyme and host-guest sections, but the paper gets way too long if this is done). Instead, focus just on the major take-aways. For example, accuracies of RMS error around 0.8 kcal/mol are possible; two studies basically agree on values of some of the ligands; the closed to open transition, etc. The idea is to tell people what they need to know (and give them references to read more) with as little extra text as possible. ....
  - DLM: Germano, you will need to remove this section below and make sure everything relevant is incorporated into your earlier section ..
- 19      21

## I. INTRODUCTION

Molecular simulations provide a powerful technique for predicting and understanding the structure, function, dynamics, and interactions of biomolecules. Often, these techniques are valued because they provide a way to actually watch what might be going on at the atomic level. However, simulations also can be used to make quantitative predictions of thermodynamic and kinetic properties, with applications in fields including drug discovery, chemical engineering, and nanoengineering. A thermodynamic property of particular interest is the binding affinity between biomolecules and ligands such as inhibitors, modulators, or activators. With accurate and rapid affinity predictions, we could use simulations in varied health-related applications, such as the prediction of biomolecular interaction networks in support of systems biology, or rapid design of new medications with reduced side-effects and drug resistance. In this work, we give a view of how these simulations could impact drug discovery, briefly discuss where they stand now, and then argue for benchmark systems chosen to drive and assess the advancement of these methods, helping to make them practical for drug discovery.

### A. Imagining a tool for drug discovery

A major aim in the development of molecular simulations is to create quantitative, accurate tools which will guide early stage drug discovery. Consider a medicinal chemist in the not-too-distant future who has just finished synthesizing several new derivatives of an existing inhibitor as potential drug leads targeting a particular biomolecule, and has obtained binding affinity or potency

data against the desired biomolecular target. Before leaving work, he or she generates ideas for perhaps 100 new compounds which could be synthesized next, then sets a computer to work overnight prioritizing them. By morning, the compounds have all been prioritized based on reliable predictions of their affinity for the desired target, selectivity against alternative targets which should be avoided, solubility, and membrane permeability. The chemist then looks through the predicted properties for the top few compounds and selects the next ones for synthesis. If synthesizing and testing each compound takes several days, this workflow compresses roughly a year's work into a few days.

While this workflow is not yet a reality, huge strides have been made in this direction, with calculated binding affinity predictions now showing real promise [28, 29, 39, 44, 141, 180, 208, 216], solubility predictions beginning to come online [119, 161, 177], and predicted drug resistance/selectivity also apparently tractable [115], with some headway apparent on membrane permeability [35, 111]. A considerable amount of science and engineering still remains to be done to make this vision a reality, but, given recent progress, the question now seems more one of *when* rather than *whether*.

### B. Increasing accuracy will yield increasing payoffs

Recent progress in computational power, especially the widespread availability of graphics processing units (GPUs) and advances in automation [121] and sampling protocols, have helped simulation-based techniques reach the point where they now appear to have sufficient accuracy to be genuinely useful in guiding pharmaceutical drug discovery, at least for a certain subset of problems [28, 39, 90, 135, 180, 208, 216]. Specifically, in some situations, free energy calculations appear to be capable of achieving RMS errors in the 1-2 kcal/mol range with current force fields, even in prospective applications. As a consequence, pharmaceutical companies are beginning to use these methods in discovery projects. The most immediate application of these techniques is to guide synthesis for lead optimization, but applications to scaffold hopping and in other areas also appear possible.

At the same time, it is clear that not all situations are so favorable, so it is worth asking what level of accuracy is actually needed. It is often suggested that we need binding free energy predictions accurate to within  $\sim 1$  kcal/mol, but we are not aware of a clear basis for this figure beyond the fact it is a pleasingly round number that is close to the thermal kinetic energy,  $RT$ . Instead of setting a single threshold requirement for accuracy, it is more informative to consider how accurate calculations must be to reduce the number of compounds synthesized and tested by some factor, relative to the number required without computational prioritization. If one targets a three-fold reduction, the answer appears to be that calculations with a 2 kcal/mol RMS error will suf-

fice [141, 186]. Thus, one can gain substantial benefit from simulations that are good yet still quite imperfect.

More broadly, though, this analysis does not address the net value of computational affinity predictions in drug discovery. Costs include those of the software, computer time, and personnel required to incorporate calculations into the workflow; while benefits include the savings, revenue gains, and externalities attributable to reducing the number of low-affinity compounds synthesized and arriving earlier at a potent drug candidate. In addition, with sufficiently reliable predictions, chemists may choose to tackle difficult synthesis efforts they otherwise might have avoided, resulting in more novel and valuable chemical matter.

### C. Overview of free energy calculations

The present review focuses on a class of methods in which free energy differences are computed with simulations that sample Boltzmann distributions of molecular configurations. These samples are usually generated by molecular dynamics (MD) simulations [101], with the system effectively coupled to a heat bath at constant temperature, but Monte Carlo methods may also be used [33, 131, 132]. In either case, the energy of a given configuration is provided by a potential function, or force field, which estimates the potential energy of a system of solute and solvent molecules as a function of the coordinates of all of its atoms. Such simulations may be used in several different ways to compute binding free energies or relative binding free energies, as detailed elsewhere [27, 30, 132, 185] and summarized below. In all cases, however, the calculations yield the free energy difference between two states of a molecular system, and they do so by computing the reversible work for changing the initial state to the final one. Two broad approaches deserve mention.

The first general approach directly computes the standard binding free energy of two molecules via evaluating the reversible work of transferring the ligand from the binding site into solution. (This is sometimes called an absolute binding free energy calculation.) The pathway of this change may be one that is physically realizable, or one that is only realizable *in silico*, in which case it is sometimes called an “alchemical” pathway. Physical pathway methods provide the standard binding free energy by computing the reversible work of, in effect, pulling the ligand out of the binding site. Although, by definition, the pathway used must be a physical one that could occur in nature, it need not be probable, and improbable pathways, governed by an order parameter specifying how far the ligand is from the binding site, are often used [13, 86, 91, 207, 221, 231]. In addition, artificial restraints may be useful to avoid sampling problems in the face of often complex barriers along the pathway [13, 86, 91, 207, 221]. By contrast, alchemical pathway methods artificially decouple the ligand from the bind-

ing site and then recouple it to solution from the protein [14, 78, 87, 100, 137]. Although alchemical decoupling methods may avoid clashes of the ligand with the protein that might be problematic when pathway methods are applied to a protein with a buried binding site, they still can pose some of the same sampling challenges. For example, sampling of the unbound receptor must be adequate after the ligand is removed, and water molecules must have time to equilibrate in the vacated binding site. Given that free energy is a state function, it is not surprising that alchemical and physical pathway approaches yield apparently comparable results when applied to the same systems [42, 83, 114, 230].

The second general approach computes the difference between the binding free energies of two different ligands for the same receptor, by computing the work of artificially converting one ligand into another, first in the bound state and then free in solution [27, 30, 132, 203]. Because these conversions are not physically realizable, such calculations are, again, called alchemical. These calculations can be quite efficient if the two ligands are very similar to each other, but they become more complicated and pose greater sampling problems if the two ligands are very different chemically or if there is a high barrier to interconversion between their most stable bound conformations [121]. In addition, there may be concerns about slow conformational relaxation of the protein in response to the change in ligand. Nonetheless, alchemical relative free energy calculations currently are the best automated and most widely used free energy methods [121, 141, 216].

The accuracy and precision of all of these methods are controlled by three major considerations. First, many conformations typically need to be generated, or sampled, in order to obtain an adequate representation of the Boltzmann distribution. In the limit of infinite sampling, a correctly implemented method would yield the single value of the free energy difference dictated by the specification of the molecular system and the chosen force field. In reality, however, only finite sampling is possible, so the reported free energy will differ from the nominal value associated with infinite sampling. In addition, because sampling methods are typically stochastic and the dynamics of molecular systems are sensitive to initial conditions [4], repeated calculations, using different random number seeds or initial states, will yield somewhat different results. The problem of finite sampling is most acute for systems where low-energy (hence highly occupied) conformational states are separated by high effective barriers, whether energetic or entropic. Second, even if adequate sampling is achievable, free energy differences may disagree substantially with experiment if the force field is not sufficiently accurate. Third, errors may also arise if the representation of the system in the simulation does not adequately represent the actual system, e.g. if protonation states are assigned incorrectly and held fixed.

## D. Challenges and the domain of applicability

Thus, in order for a free energy calculation to be reliable, it must use an appropriate representation of the physical system and an accurate force field, and it must adequately sample the relevant molecular configurations. In the case of the more widely used alchemical relative free energy approach, this means that the best results are expected when:

- a high quality receptor structure is available, without missing loops or other major uncertainties
- the protonation state of the ligand and binding-site residues (as well as any other relevant residues) can reliably be inferred
- the ligand binding mode is defined by crystallographic studies and is not expected to change much on modification
- the receptor does not undergo substantial, slow conformational changes
- key interactions are expected to be well-described by underlying force fields

Beyond this domain of applicability—whose dimensions are, in fact, still somewhat vague [1]—substantial challenges may be encountered. For example, binding free energy calculations for a cytochrome C peroxidase mutant suggest limitations of fixed-charge force fields. In this case, the strength of electrostatic interactions in a buried, relatively nonpolar binding site appears to be overestimated by a conventional fixed-charge force field, likely due to underestimation of polarization effects [172]. Sampling problems are also common, with slow sidechain rearrangements and ligand binding mode rearrangements in model binding sites in T4 lysozyme posing timescale problems unless enhanced or biased sampling methods are carefully applied [17, 68, 95, 138, 140, 215]; and larger-scale protein motions induced by some ligands can also pose challenges [17, 117].

Although such problems need not prevent free energy calculations from being used, they can require specific adjustment of procedures and parameters based on experience and knowledge of the system at hand. Thus, a key challenge for the field is how to use insights from well-studied cases to enable automation and reduce the detailed knowledge of each system required to carry out high quality simulations.

Troubleshooting is also a major challenge. In most cases where calculations diverge substantially from experiment, the reason for the discrepancy is not apparent. Is the force field inaccurate? Would the results improve with more sampling? Were protonation states misassigned—or do they perhaps even change on binding? There might even be a software bug [50] or a human error in the use of the software. As a consequence, it is not clear what steps are most urgently needed to advance the field as a whole. In this work, we argue that many of these problems can be alleviated, and that the field will advance more rapidly, if we select a set of well-

chosen benchmark systems on which free energy methods are regularly tested.

## E. Improving modeling by cycles of testing, prediction, and improvement

Modeling can in some cases improve rapidly, but, in our experience, rapid advances are most common when computational models undergo regular cycles of improvement, predictive testing, learning, and then further improvement. This can be particularly difficult for academic groups which may not have the resources for predictive tests; however, these are essential, since it is only in predictive tests that we can be sure we are assessing the performance of a method as it works in real life, rather than relying on knowledge of the expected outcome to inform setup of the calculations. With this in mind, the Statistical Assessment of the Modeling of Proteins and Ligands (SAMPL) blind challenges, as well as the Community Structure Activity Resource (CSAR) challenge, later replaced by the Drug Design Data Resource (D3R) grand challenges, have arisen to meet part of this need. Currently, D3R focuses on running blind challenges on protein-ligand binding with datasets from the pharmaceutical industry, allowing testing and evaluation of computational methods on systems of direct pharmaceutical relevance. SAMPL, in contrast, focuses on predictions in simpler physical settings [139], such as small molecules in aqueous and organic phases, and small molecules binding to supramolecular hosts. Together, the SAMPL and D3R challenges roughly span the spectrum from properties we can predict now (though they may be challenging in some cases [9, 139, 230]) to the drug binding we want to be able to reliably predict. These challenges are vital as they provide our only opportunity, at present, to routinely see how different methods compare when attempting to compute the same properties, and they provide the beginnings of a model for how we can best advance free energy techniques: routinely testing our methods on the same, well-understood systems to learn what does and doesn't work to improve performance. Thus, we need not just blind tests, but retrospective testing on well-understood, “benchmark” systems.

## II. THE NEED FOR WELL-CHOSEN BENCHMARK SYSTEMS

Although tests of individual free energy methods are not uncommon today [28, 39, 135, 208, 216], the use of nonoverlapping molecular systems and computational protocols makes it difficult to compare methods on a rigorous basis. In addition, few studies are designed to identify key sources of error and thereby focus future research and development. A few molecular systems have now emerged as *de facto* standards for general study (Section III). These selections result in part from two se-

ries of blinded prediction challenges (SAMPL [150], and CSAR [49] followed by D3R [71]), which have helped focus the computational chemistry community on a succession of test cases and highlighted the need for methodological improvements. However, broader adoption of a larger and more persistent set of test cases is needed. By coalescing around a compact set of benchmarks, well chosen to challenge and probe free energy calculations, practitioners and developers will be able to better assess and drive progress in binding free energy calculations. Our primary goals in this work are to explain how benchmark systems can be used to advance the field, to encourage adoption of a standard set of benchmark systems, and to propose some candidates for this set.

### A. Benchmark types and applications

We envision two classes of benchmark cases: “hard” benchmarks, which are simple enough that well-converged results can readily be computed; and “soft” benchmarks, for which convincingly converged results cannot readily be generated, but which are still simple enough that concerted study by the community can delineate key issues that might not arise in the simpler “hard” cases. The following subsections provide examples of how hard and soft benchmark systems may be used to address important issues in free energy simulations.

#### 1. Hard benchmarks

*a. Systems to test software implementations and usage* It is crucial yet nontrivial to validate that a simulation package correctly implements and applies the desired methods [184], and benchmark cases can help with this. First, all software packages could be tested for their ability to generate correct potential energies for a single configuration of a specified molecular system and force field. These results should be correct to within rounding error and the precision of the physical constants used in the calculations [184]. Second, different methods and software packages should give consistent binding free energies when identical force fields are applied with identical simulation setups and compositions. The benchmark systems for such testing can be simple and easy to converge, and high precision free energies (e.g., uncertainty  $\approx 0.1$  kcal/mol) should serve as a reference. Test calculations should typically agree with reference results to within 95% confidence intervals, from established methods [62, 183]. For this purpose, the correctly computed values need not agree with experiment; indeed, experimental results are unnecessary.

*b. Systems to check sampling completeness and efficiency* As discussed above, free energy calculations require thorough sampling of molecular configurations from the Boltzmann distribution dictated by the force field that is employed. This sampling is typically done by run-

ning molecular dynamics simulations, and for systems as large and complex as proteins, it is difficult to carry out long enough simulations. Calculations with inadequate sampling yield results that are imprecise, in the sense that multiple independent calculations with slightly different initial conditions will yield significantly different results, and these ill-converged results will in general be poor estimates of the ideal result obtained in the limit of infinite sampling. Advanced simulation methods have been developed to speed convergence [185, 200], but it is not always clear how various methods compare to one another. To effectively compare such enhanced sampling methods, we need benchmark molecular systems, parameterized with a force field that many software packages can use, that embody various sampling challenges, such as high dimensionality, and energetic and entropic barriers between highly occupied states, but which are just tractable enough that reliable results are available via suitable reference calculations. Again, experimental data are not required, as the main purpose is to test and compare the power of various enhanced sampling technologies.

*c. Systems to assess force field accuracy* Some molecular systems are small and simple enough that current technology allows thorough conformational sampling, and hence well converged calculations of experimental observables. This has long been feasible for liquids [99]; for example, it is easy to precisely compute the heat of vaporization of liquid acetone with one of the standard force fields. More recently, advances in hardware and software have made it possible to compute binding thermodynamics to high precision for simple molecular recognition systems [86], as further discussed below. In such cases, absent complications like uncertain protonation states, the level of agreement with experiment reports directly on the accuracy of the force field. Thus, simple molecular recognition systems with reliable experimental binding data represent another valuable class of benchmarks. Here, of course, experimental data are needed. Ideally, the physical materials will be fairly easy to obtain so that measurements can be replicated, and new experimental conditions, such as different temperatures and solvent compositions, can be explored.

#### 2. Soft benchmarks

*a. Systems to challenge conformational sampling techniques* Enhanced sampling techniques (Section II A 1 b), designed to speed convergence of free energy simulations, may not be adequately tested by any hard benchmark, because such systems are necessarily rather simple. Thus, despite the fact that reliable reference results are not available for soft benchmarks, they are still important for method comparisons. For example, it may become clear that some methods are better at sampling in systems with high energy barriers, and others in high-dimensional systems with rugged energy surfaces. Devel-

opers should test methods on a standard set of benchmark systems for informative comparisons.

*b. Direct tests of protein-ligand binding calculations*

Although it is still very difficult to convincingly verify convergence of many protein-ligand binding calculations, it is still important to compare the performance of various methods for these real-world challenges. Appropriate soft benchmarks are likely to be cases which are still not overly challenging, involving small proteins and simple binding sites. We propose defining a series of benchmark protein-ligand systems that systematically introduce specific challenges. In particular, they should exemplify none, one, two, or  $N$  of the following challenges, in various combinations:

1. Sampling challenges

- (a) Sidechains in the binding site rearrange on binding different ligands
- (b) Modest backbone conformational changes, such as loop motion
- (c) Large scale conformational changes, such as domain motions and allostery
- (d) Ligand binding modes change unpredictably with small chemical modifications
- (e) High occupancy water sites rearrange depending on bound ligand

2. System challenges

- (a) Protonation state of ligand and/or protein changes on binding
- (b) Multiple protonation states of the ligand and/or receptor are relevant, due to  $pK_a$ s near the experimental pH, or the presence of multiple relevant tautomers
- (c) Results are sensitive to buffer, salts or other environmental factors

3. Force field challenges

- (a) Strong electric fields suggest that omission of explicit electronic polarizability will limit accuracy
- (b) Ligands interact directly with metal ions
- (c) Ligands or co-factors challenge existing force fields

*c. Progression of soft benchmarks* We envision these more complex benchmark systems proceeding through stages, initially serving effectively as a playground where major challenges and issues are explored, documented, and become well-known. Eventually, some will become sufficiently well characterized and sampled that they become hard benchmarks.

## B. Applications and limitations of benchmark systems

Benchmark systems along the lines sketched above will allow potential advances in computational methods to be tested in a straightforward, reproducible manner. For example, force fields may be assessed by swapping new parameters, or even a new functional form, into an ex-

isting workflow to see the impact on accuracy for a hard benchmark test. Sampling methods may be assessed by using various enhanced sampling methods for either hard or soft sampling benchmarks, here without focusing on accuracy relative to experiment. And system preparation tools could be varied to see how different approaches to assigning protonation states, modeling missing loops, or setting initial ligand poses, affect agreement of receptor-ligand binding calculations with experiment—with the understanding that force field and sampling also play a role. Finally, comparisons across methods will be greatly facilitated by community acceptance of a set of standard cases: well-characterized and studied benchmarks utilized by the majority of developers and research groups, ideally on a routine basis.

At the same time, there is a possibility that some methods will inadvertently end up tuned specifically to generate good results for the set of accepted benchmarks. In such cases, the results for systems outside the benchmark set might still be disappointing. This means the field will need to work together to develop a truly representative set of benchmarks. This potential problem can also be mitigated by sharing of methods to enable broader testing by non-developers, and by participation in blinded prediction challenges, such as SAMPL and D3R, which confront methods with entirely new challenge cases.

## III. CURRENT BENCHMARK SYSTEMS FOR BINDING PREDICTIONS

No molecular systems have yet been designated by the field as benchmarks for free energy calculations, but certain test cases have proven particularly helpful and been widely studied, including specific host molecules, certain designed binding sites in the enzyme T4 lysozyme, and some bromodomain binding sites. Here, we describe the artificial and biological receptors considered and propose specific host-guest and ligand-receptor combinations as initial benchmark systems for free energy calculations.

We also point to several additional hosts and small proteins that also have potential to generate useful benchmarks in the future (Section IV). We focus on cases where experimental data are available and add value, rather than cases chosen to test conformational sampling methods, for which experimental data are not required (Section II A).

### A. Host-guest benchmarks

Chemical hosts are small molecules, often comprising fewer than 100 non-hydrogen atoms, with a cavity or cleft that allows them to bind other compounds, called guests, with significant affinity. Hosts bind their guests via the same basic forces that proteins used to bind their ligands, so they can serve as simple test sys-

tems for computational models of noncovalent binding. Moreover, their small size, and, in many cases, their rigidity, can make it feasible to sample all relevant conformations, making for “hard” benchmarks as defined above (Section II A). Furthermore, experiments can often be run under conditions that make the protonation states of the host and guest unambiguous. Under these conditions, the level of agreement of correctly executed calculations with experiment effectively reports on the validity of the force field (Section II A 1c). For a number of host-guest systems, the use of isothermal titration calorimetry (ITC) to characterize binding provides both binding free energies and binding enthalpies. Binding enthalpies can often also be computed to good numerical precision [86], so they provide an additional check of the validity of simulations. A variety of curated host-guest binding data is available on BindingDB at <http://bindingdb.org/bind/HostGuest.jsp>.

Hosts fall into chemical families, such that all members of each family share a major chemical motif, but individuals vary in terms of localized chemical substitutions and, in some families, the number of characteristic monomers they comprise. For example, all members of the cyclodextrin family are chiral rings of glucose monomers; family members then differ in the number of monomers and in the presence or absence of various chemical substituents. For tests of computational methods ultimately aimed at predicting protein-ligand binding affinities in aqueous solution, water soluble hosts are, arguably, most relevant. On the other hand, host-guest systems in organic solvents may usefully test how well force fields work in the nonaqueous environment within a lipid membrane. Here, we focus on two host families, the cucurbiturils [63, 144] and the octa-acids (more generally, Gibb deep cavity cavitands) [74, 89]. These have already been the subject of concerted attention from the simulation community, due in part to their use in the SAMPL blinded prediction challenges [150, 152, 230].

### 1. Cucurbiturils

The cucurbiturils (**Figure 1**) are achiral rings of glycoluril monomers [63]. The first characterized family member, cucurbit[6]uril, has six glycoluril units, and subsequent synthetic efforts led to the five-, seven-, eight- and ten-monomer versions, cucurbit[n]uril ( $n=5,6,7,8,10$ ) [120], which have been characterized to different extents. The  $n=6,7,8$  variants accommodate guests of progressively larger size, but are consistent in preferring to bind guests with a hydrophobic core sized to fit snugly into the relatively nonpolar binding cavity, along with at least one cationic moiety (though neutral compounds do bind [112, 223]) that forms stabilizing interactions with the oxygens of the carbonyl groups fringing both portals of the host [120]. Although derivatives of these host molecules have been made [5, 36, 113, 210], most of the binding data published for this class of

hosts pertain to the non-derivatized forms. A fairly extensive set of data is available in BindingDB at <http://bindingdb.org/bind/HostGuest.jsp>.

We propose cucurbit[7]uril (CB7) as the basis of one series of host-guest benchmark systems (**Figure 1**). This host is convenient experimentally, because it is reasonably soluble in water; and computationally, because it is quite rigid and lacks acidic or basic groups. In addition, it has attracted particular interest because of the high binding affinities of some guests, exceeding even the tightest-binding protein-ligand systems [22, 120, 145, 171]. Finally, CB7 is already familiar to a number of computational chemistry groups, as it figured in two of the three SAMPL challenges that included host-guest components [150, 152], and it is currently the focus of the “hydrophobe challenge” [178].

*a. CB7 presents several challenges* Despite the simplicity of CB7, calculations of its binding thermodynamics are still challenging, with several known complexities:

1. **Tight exit portal:** Guest molecules with bulky hydrophobic cores, such as adamantyl or [2.2.2]bicyclooctyl [145, 146] groups, do not fit easily through the constrictive portals [206]. As a consequence, free energy methods which compute the work of binding along a physical dissociation pathway may encounter a high barrier as the bulky core exits the cavity, and this can lead to subtle convergence problems [86, 207]. One way to solve this problem is to reversibly add restraints that open the portal, then remove the guest, and finally reversibly remove the restraints [86], including all of these contributions in the overall work of dissociation.
2. **Water binding and unbinding:** If one computes the work of removing the guest from the host by a nonphysical pathway, in which the bound guest is gradually decoupled from the host and surrounding water [78], large fluctuations in the number of water molecules within the host’s cavity can occur when the guest is partly decoupled, and these fluctuations can slow convergence [175].
3. **Salt concentration and buffer conditions:** Binding thermodynamics are sensitive to the composition of dissolved salts, both experimentally [145, 146, 150] and computationally [91, 153]. As a consequence, to be valid, a comparison of calculation with experiment must adequately model the experimental salt conditions.
4. **Finite-size artifacts due to charge modification:** Because many guest molecules carry net charge, it should be ascertained that calculations in which guests are decoupled from the system do not generate artifacts related to the treatment of long-ranged Coulombic interactions [118, 169, 173, 188].

*b. The proposed CB7 benchmark sets comprise two compound series* For CB7, we have selected two sets of guests that were studied experimentally under uniform conditions (50 mM sodium acetate buffer, pH 4.74, 298K)




FIG. 1: Three host molecules, CB7, OA, and TEMOA, used in the host-guest benchmark sets. The first two are variants of the octa-acid GDCC, and the third is a cucurbituril. Guest structures are available in the supplemental material. Top row highlights the constituent monomers; middle and bottom rows show views into the binding sites and from the sides, respectively.

by one research group [22, 120]. Each series is based on a common chemical scaffold, making it amenable to not only absolute but also alchemical relative free energy calculations (Section 1C). One set is based on an adamantane core (**Table I**), and the other on an aromatic ring (**Table II**). These systems can be run to convergence to allow detailed comparisons among methods and with experiment. Their measured binding free energies range from -5.99 to -17.19 kcal/mol, with the adamantane series spanning a particularly large range.

*c. Prior studies provide additional insight into CB7's challenges* Sampling of the host appears relatively straightforward in CB7 as it is quite rigid and its symmetry provides for clever convergence checks [86, 147]. Due to its top-bottom symmetry, flips of guests from “head-in” to “head-out” configurations are not necessary to obtain convergence [54]. However, sampling of the guest geometry can be a challenge, with transitions

between binding modes as slow as 0.07 flips/ns [147], and flexible guests also presenting challenges [147]. As noted above, water sampling can also be an issue, with wetting/dewetting transitions occurring on the 50 ns timescale [175] when the guest is partly decoupled from the aqueous host in alchemical calculations.

Salt and buffer conditions are also key. In addition to the strong salt-dependence of binding [146], acetic acid (such as in a sodium acetate buffer) can compete with guests for the binding site [145]. This may partially explain systematic errors in some computational studies [91, 153]. Indeed, the difference between 50 mM sodium acetate buffer and 100 mM sodium phosphate buffer impacts measured binding free energies by 2.5-2.8 kcal/mol [150, 153]. Cationic guests could also have substantial and differing interactions with the counterions in solution, potentially lowering affinity relative to zero-salt conditions [150]. Additionally, CB7 can also bind cations

fairly strongly [21, 92, 127]. Thus, one group found a 6.4-6.8 kcal/mol dependence on salt concentration [91] (possibly due to cation competition for the binding site), possibly impacting other studies as well [147].

Despite these issues, CB7 appears to be at the point where careful studies can probe the true accuracy of our force fields [70, 86, 91, 151, 228], and the results can be sobering, with root mean square (RMS) errors in the binding free energies as high as 8 kcal/mol [86, 147]. More encouragingly, the values of  $R^2$  values can be as high as 0.92 [86]. Calculated values are in many cases quite sensitive to details of force field parameters [146, 147, 151]. For example, modest modification of some Lennard-Jones parameters yielded dramatic improvements in calculated values [228], and host-guest binding data has, accordingly, been suggested as an input for force field development [70, 86, 228]. Water structure around CB7 and calculated binding enthalpies also appear particularly sensitive to the choice of water model [54, 70, 175], and water is clearly important for modulating binding [157]. The water model also impacts the number of sodium ions which must be displaced (in sodium-based buffer) on binding [70, 86].

In summary, CB7 is still a challenging benchmark that can put important issues into high relief. For example, in SAMPL4, free energy methods yielded  $R^2$  values from 0.1 to 0.8 and RMS errors of about 1.9 to 4.9 kcal/mol for the same set of CB7 cases [150]. This spread of results across rather similar methods highlights the need for shared benchmarks. Potential explanations include convergence difficulties, subtle methodological differences, and details of how the methods were applied. Until the origin of such discrepancies is clear, it is difficult to know how accurate our methods truly are.

To aid the adoption of these systems as benchmarks, input files for the CB7 systems proposed here are available in our GitHub repository.

## 2. *Gibb Deep Cavity Cavitands (GDCC)*

The octa-acids (OA) (**Figure 1**) are synthetic hosts with deep, basket-shaped, hydrophobic binding sites [74]. The eight carboxylic acidic groups for which they were originally named make these hosts water-soluble, but do not interact directly with bound hosts; instead, they project outward into solvent. Binding data have been reported for the original form of this host (OA) [74] and for a derivative with four added methyl groups at equivalent locations in the entryway, where they can contact a bound guest (TEMOA) [69, 197]. (Note that OA and TEMOA have also been called OAH and OAME, respectively [230].) Additional family members with other substituents around the portal have been reported, as has a new series in which the eponymous carboxylic groups are replaced by various other groups, including a number of basic amines [89]. However, we are not aware of binding data for these derivatives. Because these closely re-

lated hosts are clearly in the same family but do not have eight acidic groups, and in recognition of the family's developer, we propose the more general name Gibb deep cavity cavitands (GDCCs) for this family of hosts. The binding cavities of the GDCCs are fairly rigid, though less so than the cucurbiturils. Some simulators report "breathing" motions that vary the diameter of the entry by up to 8 Å [134]; and, in some studies, the benzoic acid "flaps" around the entry occasionally flip upward and into contact with the guest [204, 229], though this motion has not been verified experimentally. Additionally, the four priopionate groups protruding into solution from the exterior base of the cavity are all flexible.

The octa-acids tend to bind guest molecules possessing a hydrophobic moiety that fits into the host's cavity and a hydrophilic moiety that projects into the aqueous solvent. Within these specifications, they bind a diversity of ligands, including both organic cations and anions, as well as neutral compounds with varying degrees of polarity [75, 77]. Compounds with adamantane or noradamantane groups display perhaps the highest affinities observed so far, with binding free energies ranging to about -8 kcal/mol [198]. Many of the experimental binding data comes from ITC, so binding enthalpies are often available.

Two experimental aspects of binding are particularly intriguing and noteworthy. First, the binding thermodynamics of OA is sensitive to the type and concentration of anions in solution. Although NaCl produces relatively modest effects, 100 mM sodium perchlorate, chloride and isothiocyanate can shift binding enthalpies by up to about 10 kcal/mol and free energies by around 2 kcal/mol [76]. These effects are due in part to binding of anions by the host; indeed, trichloroacetate is reported to bind OA with a free energy of -5.2 kcal/mol [192], and competition of other guests with bound anions leads to entropy-enthalpy tradeoffs. Second, elongated guests can generate ternary complexes, in which two OA hosts encapsulate one guest, especially if both ends of the guest are not very polar [75].

*a. The proposed GDCC benchmark sets are drawn from SAMPL* We propose the establishment of two GDCC benchmark sets, based on data which formed part of the SAMPL4 and SAMPL5 challenges. One set is based on experiments carried out in phosphate buffer at pH 11.5, and the other on experiments in tetraborate buffer at pH 9.2. The guests in the first set (Table III) are adamantane derivatives and cyclic (aromatic and saturated) carboxylic acids (Table III), which bind to hosts OA and TEMOA with free energies of -3.7 to -7.6 kcal/mol. The second set of guests (Table IV) comprises carboxylic acids based on phenyl and cyclohexane cores. Both sets offer aqueous binding data with free energies spanning about 4 kcal/mol, frequently along with binding enthalpies. The hosts and many or all of their guests are small and rigid enough to allow convincing convergence of binding thermodynamics with readily feasible simulations; and, like the cucurbiturils, they are already emerg-

TABLE I: Proposed CB7 Set 1 benchmark data

ID <sup>a</sup>	name	PC CID <sup>b</sup>	2D	SMILES	$\Delta G^c$ (kcal/mol)
1	memantine	4054		CC12CC3CC(C1)(CC(C3)(C2)N)C	$-5.99 \pm 0.05$ <sup>d</sup>
3	1,3-bis(trimethylaminio)adamantane	101379195		C[N+] (C) (C)C12CC3CC(C1)CC(C3)(C2)[N+] (C) (C)C	$-6.55 \pm 0.05$ <sup>d</sup>
5	N-(1-adamantyl)ethylenediamine	303798		C1C2CC3CC1CC(C2)(C3)NCCN	$-18.22 \pm 0.09$ <sup>e</sup>
17	adamantane-1,3-diamine	213512		C1C2CC3(CC1CC(C2)(C3)N)N	$-11.33 \pm 0.05$ <sup>d</sup>
18	1-adamantanecarboxylic acid	13235		C1C2CC3CC1CC(C2)(C3)C(=O)O	$-11.59 \pm 0.06$ <sup>d</sup>
22	1-Adamantyltrimethylaminium	3010127		C[N+] (C) (C)C12CC3CC(C1)CC(C3)C2	$-16.66 \pm 0.08$ <sup>d</sup>
23	amantadine	2130		C1C2CC3CC1CC(C2)(C3)N	$-17.19 \pm 0.08$ <sup>d</sup>
24	N-(1-adamantyl)pyridinium	3848257		C1C2CC3CC1CC(C2)(C3)[N+]4=CC=CC=C4	$-16.75 \pm 0.07$ <sup>d</sup>

<sup>a</sup> Compound ID from original paper; <sup>b</sup> PubChem Compound ID; <sup>c</sup> Standard binding free energy, where all measurements were done via NMR in 50mM sodium acetate buffer in  $D_2O$  at pH 4.74 and 298 K. Uncertainties are obtained by taking the reported standard deviations across triplicate measurements [93] and dividing by  $\sqrt{3}$ ; <sup>d</sup> drawn from [120]; <sup>e</sup> drawn from [22].

ing as *de facto* computational benchmarks, due to their use in the SAMPL4 and SAMPL5 challenges [150, 230].

*b.* *The GDCC hosts introduce new challenges beyond CB7* Issues deserving attention when interpreting the experimental data and calculating the binding thermodynamics of these systems include the following:

- 1. Tight exit portal:** The methyl groups of the TEMOA variant narrow the entryway and can generate a barrier to the entry or exit of guest molecules with bulky hydrophobic cores, though the degree of constriction is not as marked as for CB7 (above). The TEMOA methyl groups can additionally hinder sampling of guest poses in the bound state, leading to convergence problems [230]
- 2. Host conformational sampling:** Although the flexible propionate groups are not proximal to the binding cavity, they are charged and so can have long-ranged interactions. As a consequence, it may be important to ensure their conformations are well sampled, though motions may be slow [134]. Similarly, benzoic acid flips [204, 229] could potentially be an important challenge in some force fields.

**3. Water binding and unbinding:** Water appears to undergo slow motions into and out of the OA host, on timescales upwards of 5 ns [52]. This poses significant challenges for some approaches, such as metadynamics, where deliberately restraining water to stay out of the cavity when the host is not bound (and computing the free energy of doing so) can help convergence [13], and perhaps for other methods as well.

**4. Salt concentration and buffer conditions:** As in the case of CB7, binding to GDCCs is modulated by the composition of dissolved salts, both experimentally [76, 192] and computationally [160, 204]. As a consequence, to be valid, a comparison of calculation with experiment must adequately model the experimental salt conditions.

**5. Finite-size artifacts due to charge modification:** As for CB7, it should be ascertained that calculations in which charged guests are decoupled from the system do not generate artifacts related to long range Coulomb interactions. [118, 169, 173, 188].

TABLE II: Proposed CB7 Set 2 benchmark data

ID <sup>a</sup>	name	PC CID <sup>b</sup>	2D	SMILES	$\Delta G^{c,d}$ (kcal/mol)
2	dopamine	681		c1cc(c(cc1CCN)O)O	-6.31 ± 0.05
4	o-phenylenediamine	7243		c1ccc(c(c1)N)N	-6.68 ± 0.05
5	m-phenylenediamine	7935		c1cc(cc(c1)N)N	-6.69 ± 0.02
7	4-(aminomethyl)pyridine	77317		c1cnccc1CN	-7.56 ± 0.06
8	p-phenylenediamine	7814		c1cc(ccc1N)N	-8.60 ± 0.06
9	p-toluidine	7813		Cc1ccc(cc1)N	-9.43 ± 0.05
20	p-xylylenediamine	68315		c1cc(ccc1CN)CN	-12.62 ± 0.06

<sup>a</sup> Compound ID from original paper; <sup>b</sup> PubChem Compound ID; <sup>c</sup> Standard binding free energy, where all measurements were done via NMR in 50mM sodium acetate buffer in  $D_2O$  at pH 4.74 and 298 K. Uncertainties are obtained by taking the reported standard deviations across triplicate measurements [93] and dividing by  $\sqrt{3}$ ; <sup>d</sup> drawn from [120].

**6. Protonation state effects:** Although experiments are typically run at pH values that lead to well-defined protonation states of the host and its guests, this may not always hold [52, 150, 204], particularly given experimental evidence for extreme binding-driven  $pK_a$  shifts of 3-4 log units for some carboxylate compounds [192, 214]. Thus, attention should be given to ionization states and their modulation by binding.

*c. Prior studies provide additional insight into the challenges of OA* As noted, two different host conformational sampling issues have been observed, with dihedral transitions for the propionate groups occurring on 1-2 ns timescales [134]); motions of the benzoic acid flaps were also relatively slow [204, 229] though perhaps thermodynamically unimportant. Guest sampling can also be an issue, at least in TEMOA [230], and this host's tight cavity may also have implications for binding entropy [229].

Salt concentration strongly modulates binding affinity, at least for anions, and the nature of the salt also plays an important role [23]. Co-solvent anions can also increase or decrease binding depending on their identity [76]. Some salts even bind to OA themselves, with perchlorate [76] and trichloroacetate [192] being particularly potent, and thus will compete with guests for binding. Computationally, including additional salt beyond that needed for system neutralization changed binding free energies by up to 4 kcal/mol [204].

Although the protonation states of the guests might seem clear and unambiguous, experimental evidence also indicates major  $pK_a$  shifts on binding so that species such as acetate, formate and others could bind in neutral

form at neutral pH [192, 214]. One study used absolute binding free energy calculations for different guest charge states, coupled with  $pK_a$  calculations, and found that inclusion of  $pK_a$  corrections and the possibility of alternate charge states of the guests affected calculated binding free energies by up to 2 kcal/mol [204]. Even the host protonation state may be unclear. Although OA might be assumed to have all eight carboxylic acids deprotonated at the basic pH of typical experiments, the four at the bottom are in close proximity, and these might make hydrogen bonds allowing retention of two protons [52]. Thus, there are uncertainties as to the host protonation state [52, 150], which perhaps also could be modulated by guest binding.

The challenges of system definition and conformational sampling appear to be greater for OA and TEMOA than for CB7, as discussed above, so it is harder to draw definite conclusions regarding force field accuracy and differences among force fields. Thus, although there have been some comparisons of charge [134, 147, 150] and water models [229], the resulting differences in computed binding thermodynamics so far seem mostly inconclusive or at least not that large. Similarly, OPLS and GAFF results did not appear dramatically different in accuracy [13]. It is worth noting that several groups using different computational approaches but the same force field and water model in SAMPL5 did not obtain identical binding free energies [13, 15, 230]. Some of these issues were resolved in follow-up work [13], bringing the methods into fairly good agreement for the majority of cases [15, 229].

To aid the adoption of these systems as benchmarks, input files for the GDCC systems proposed here are available in our GitHub repository.

TABLE III: Proposed GDCC Set 1 benchmark data

ID <sup>a</sup>	SAMPL <sup>b</sup>	name	PC CID <sup>c</sup>	2D	SMILES	$\Delta G^c$ (kcal/mol)	$\Delta H^d$ (kcal/mol)
OA host							
3	OA-G1	5-hexynoic acid	143036		C#CCCCCC(=O)O	-5.400 ± 0.003	-7.71 ± 0.05
4	OA-G6	3-nitrobenzoic acid	8497		c1cc(cc(c1)[N+](=O)[O-])C(=O)O	-5.340 ± 0.005	-5.67 ± 0.01
5	OA-G2	4-cyanobenzoic acid	12087		c1cc(ccc1C#N)C(=O)O	-4.73 ± 0.01	-4.45 ± 0.08
6	OA-G4	4-bromo adamantane-1-carboxylic acid	12598766		C1C2CC3CC(C2)(CC1C3Br)C(=O)O	-9.37 ± 0.01	-14.78 ± 0.02
7	OA-G3	N,N,N-trimethylhexan-1-aminium	84774		CCCCC[N+](C)(C)C	-4.49 ± 0.01	-5.91 ± 0.10
8	OA-G5	trimethylphenethylaminium	14108		Cc1cccc1CC(C)(C)[NH3+]	-3.72 ± 0.01	-9.96 ± 0.11
TEMOA/OAME host							
3	OA-G1	5-hexynoic acid	143036		C#CCCCCC(=O)O	-5.476 ± 0.006	-9.961 ± 0.006
4	OA-G6	3-nitrobenzoic acid	8497		c1cc(cc(c1)[N+](=O)[O-])C(=O)O	-4.52 ± 0.02	-9.1 ± 0.1
5	OA-G2	4-cyanobenzoic acid	12087		c1cc(ccc1C#N)C(=O)O	-5.26 ± 0.01	-7.6 ± 0.1
7	OA-G3	N,N,N-trimethylhexan-1-aminium	84774		CCCCC[N+](C)(C)C	-5.73 ± 0.06	-6.62 ± 0.20

<sup>a</sup> Compound ID from [197]; <sup>b</sup> SAMPL5 ID from [230]; <sup>c</sup> PubChem Compound ID; <sup>d</sup> Standard binding free energy from [197], where all measurements were done via ITC in 50 mM sodium phosphate buffer at pH 11.5 and 298 K. Uncertainties, drawn from the experimental paper, were computed from triplicate measurements taken with freshly made solutions of host and guest. However, based on personal communication with the authors, it may be advisable to regard the accuracy more conservatively, at ~2% for  $\Delta G$  and ~6% for  $\Delta H$ ; <sup>e</sup> measured binding enthalpy [197], subject to the same conditions/caveats as <sup>c</sup>. <sup>e</sup> not done.

TABLE IV: Proposed GDCC Set 2 benchmark data for binding to the OA host.

ID <sup>a</sup>	name	PC CID <sup>b</sup>	2D	SMILES	Method	$\Delta G^c$ (kcal/mol)
1	benzoic acid	243		c1ccc(cc1)C(=O)O	NMR	-3.72 ± 0.03
2	4-methylbenzoic acid	7470		Cc1ccc(cc1)C(=O)O	NMR	-5.85 ± 0.06
3	4-ethylbenzoic acid	12086		CCc1ccc(cc1)C(=O)O	ITC	-6.27 ± 0.01
4	4-chlorobenzoic acid	6318		c1cc(ccc1C(=O)O)Cl	ITC	-6.72 ± 0.01
5	3-chlorobenzoic acid	447		c1cc(cc(c1)Cl)C(=O)O	NMR	-5.24 ± 0.02
6	cyclohexanecarboxylic acid	7413		C1CCC(CC1)C(=O)O	NMR	-5.62 ± 0.04
7	trans-4-methylcyclohexanecarboxylic acid	20330		[C@H]1(CC[C@H]1(CC1)C(=O)O[H])C	ITC	-7.61 ± 0.04

<sup>a</sup> Compound ID from original paper [77]; <sup>b</sup> PubChem Compound ID; <sup>c</sup> Standard binding free energy from [77], where all measurements were done in 10 mM sodium tetraborate buffer at pH 9.2 and 298 K. A quirk is that for the NMR measurements, the guest was titrated in from 50 mM sodium tetraborate buffer, so the buffer concentration changed during the titration. Uncertainty is the standard error of the mean in free energy, computed from the reported standard deviations in  $K_a$ . Again, based on personal communication with the authors, uncertainties of perhaps 10% may be more appropriate.

## B. Protein-ligand benchmarks: the T4 lysozyme model binding sites

Although we seek ultimately to predict binding in systems of direct pharmaceutical relevance, simpler protein-ligand systems can represent important stepping stones in this direction. Two model binding sites in T4 lysozyme have been particularly useful in this regard (**Figure 2**). These two binding sites, called L99A [148, 149] and L99A/M102Q [81, 217] for point mutations which create the cavities of interest, have been studied extensively experimentally and via modeling. As protein-ligand systems, they introduce additional complexities beyond those observed in host-guest systems, yet they share some of the same simplicity. The ligands are generally small, neutral, and relatively rigid, with clear protonation states. For most ligands, substantial protein motions do not occur on binding at room temperature and ambient pressure, helping calculated binding free energies to reach apparent convergence relatively easily. However, like host-guest systems, these binding sites are still surprisingly challenging [17, 68, 95, 117, 137, 138, 140]. Thus, precise convergence is sometimes difficult to achieve, and it is in all cases essentially impossible to fully verify. As a consequence, these are “soft benchmarks” as defined above (Section II A). The utility of the lysozyme model sites is also driven by the large body of available experimental data. It has been relatively easy to identify new ligands and obtain high quality crystal structures and affinity measurements, and this has allowed two different rounds of blinded free energy prediction exercises [17, 140].

These binding sites do exhibit some surprising experimental complexities which make them interesting ongoing topics of study, such as the fact that the L99A site is empty of water when ligands are not bound [34, 116, 159] yet the protein can undergo pressure-induced filling [34, 116] or denaturation [159] which can be inhibited by binding of ligand [116, 159]. Pressure may also cause the protein to populate an excited state [108, 125] (but see [211]) which is already present to a very limited extent at equilibrium [16]. Still, as noted below, these issues do not seem to dramatically impact our ability to calculate binding free energies at standard temperature and pressure, probably in large part because these are effects which come into play only at high pressures [116, 125, 159], though as we discuss below, some ligands do induce a protein conformational change which affects the same helix as the proposed excited state [129]. It seems likely that the conformational heterogeneity observed experimentally will make lysozyme even more of a valuable benchmark system as test cases here can range from simple to challenging depending on the ligand and pressure being considered.

### 1. The apolar and polar cavities and their ligands

The L99A site is also called the “apolar” cavity. It is relatively flat and elongated, and binds mostly non-polar molecules such as benzene, toluene, p-xylene, and n-butylbenzene: basically, a fairly broad range of nonpolar planar five- and six-membered rings and ring systems (such as indole). The polar version, L99A/M102Q, introduces an additional point mutation along one edge of the binding site, providing a glutamine that introduces polarity and the potential for hydrogen bonding. It still binds a variety of nonpolar ligands such as toluene (though not benzene). One small downside of these binding sites is that the range of affinities is relatively narrow: about -4.5 to -6.7 kcal/mol in the apolar site [140, 148], and about -4 to -5.5 kcal/mol in the polar site [17]. Thus, even the strongest binders are not particularly strong, and the weakest binders tend to run up against their solubility limits. Still, these sites offer immensely useful tests for free energy calculations.

For both sites, fixed charge force fields seem to yield reasonably accurate free energies, with RMS errors of 1-2 kcal/mol, and some level of correlation with experiment, despite limited dynamic range [17, 45, 68, 140, 213]. System composition/preparation issues also do not seem to be a huge factor. Instead, sampling issues predominate:

1. Ligand orientation: These oblong binding sites are buried, and their ligands are similar in shape. Ligands with axial symmetry typically have at least two reasonably likely binding modes, but broken symmetry can drive up the number of likely binding modes. For example, phenol has two plausible binding modes in the polar cavity [17, 82] but 3-chlorophenol has at least four, three of which appear to have some population in simulations [68], because the chlorine could point in either direction within the site. Timescales for binding mode interconversion are relatively slow, with in-plane transitions on the 1-10 nanosecond timescale, and out-of-plane transitions (e.g. between toluene’s two symmetry-equivalent binding modes) taking hundreds of nanoseconds (Mobley group, unpublished data).
2. Sidechain rearrangement: Some sidechains reorganize when certain ligands, particularly larger ones, bind. This is common in particular for the side chain of Val 111 in the L99A site [95, 138, 149] and Leu 118, Val 111, and Val 103 in L99A/M102Q [17, 82, 217, 218]. These sidechain motions can be slow, due to the tight packing of the binding site, and therefore can present sampling problems for standard MD simulations [17, 95, 138, 140, 215].
3. Backbone rearrangement: Larger ligands induce shifts of the F helix (residues 107 or 108 to 115), which is adjacent to the binding site, allowing the site to enlarge. This occurs in both binding sites [17, 129, 218], but is best characterized for L99A [129]. There, addition of a series of methyl




FIG. 2: Benzene and hexylbenzene in the lysozyme L99A site, and phenol and 4,5,6,7-tetrahydroindole in the L99A/M102Q site (PDBs 4W52, 4W59, 1LI2, and 3HUA, respectively). The binding site shape is shown as a semi-transparent surface, and the protein with cartoons. In both cases, the structure with the smaller ligand is shown in green and that with the larger ligand is shown in blue. The larger ligand induces a motion of helix F bordering the binding site. Phenol and 4,5,6,7-tetrahydroindole both also bind with an ordered water (red sphere), though this does not occur for all ligands in the polar L99A/M102Q site.

groups from benzene up to n-hexylbenzene causes a conformational transition in the protein from closed to intermediate to open conformations; this affects the same region of helix F that undergoes a conformational change in the proposed excited state which is partially populated at equilibrium [16].

**Tables V and VI** introduce two initial benchmark sets based on the apolar and polar T4 lysozyme binding sites. These sets include ligands amenable to both absolute and relative free energy calculations, and have affinities that cover the currently available experimental range. Co-crystal structures are available in most cases; the corresponding PDB IDs are provided in the tables. The selected ligands span a range of challenges and levels of difficulty, ranging from fairly simple to including most of the challenges noted above. Essentially all of them have been included in at least one prior computational study, and some have appeared in a variety of prior studies. Additional known ligands and non-binders are available, with binding affinities available for 19 compounds in the L99A site [51, 140, 148] and 16 in L99A/M102Q [17, 81, 217]. Because of the extent of the sampling challenges in lysozyme, binding of most ligands will currently constitute a soft benchmark, though long-timescale simulations to turn these into hard benchmarks may already be feasible.

## 2. Computational challenges posed by the T4 lysozyme benchmarks

Early work on the lysozyme sites focused on the difficulty of predicting binding modes [17, 137, 140] because of the slow interconversions noted above. Docking methods often can generate reasonable poses spanning most of the important possibilities [17, 82, 137, 140] but do not accurately predict the binding modes of individual compounds [17, 82, 140]. Thus, binding calculations must explore multiple potential binding modes, especially as some ligands actually populate multiple poses at equilibrium [17]. In a number of studies, candidate binding modes from docking are relaxed with MD simulations, then clustered to select binding modes for further study. It turns out an effective binding free energy for each distinct candidate binding mode can be computed separately [137] and combined to find the population of each binding mode and determine the overall binding free energy. However, this is costly, since each binding mode requires a full binding free energy calculation.

Relative binding free energy calculations do not dramatically simplify the situation, as introduction of a ligand modification can leave the binding mode uncertain. For example, adding a chlorine to phenol generates at least two binding mode variants, even if the binding mode of phenol is known) [17]. A naïve solution is to consider

TABLE V: Proposed Lysozyme L99A Set benchmark data

name	PC CID <sup>h</sup>	2D	SMILES	$\Delta G^a$ (kcal/mol)	PDB code	reference
benzene <sup>b</sup>	241		c1ccccc1	-5.19 ± 0.16	181L [149], 4W52 [129]	[148]
toluene <sup>b</sup>	1140		Cc1ccccc1	-5.52 ± 0.04	4W53 [129]	[148]
ethylbenzene <sup>b</sup>	7500		CCc1ccccc1	-5.76 ± 0.07	1NHB [149], 4W54 [129]	[148]
propylbenzene <sup>b</sup>	7668		CCCc1ccccc1	-6.55 ± 0.02	4W55 [129]	[148]
butylbenzene <sup>b</sup>	7705		CCCCc1ccccc1	-6.70 ± 0.02	186L [149], 4W57 [129]	[148]
hexylbenzene <sup>b</sup>	14109		CCCCCCc1ccccc1	UNK <sup>c</sup>	4W59 [129]	[148]
p-xylene <sup>d</sup>	7809		Cc1ccc(cc1)C	-4.67 ± 0.06	187L [149]	[148]
benzofuran	9223		c1ccc2c(c1)cco2	-5.46 ± 0.03	182L [149]	[148]
thieno[2,3-c]pyridine	9224		c1cncc2c1ccs2	NB <sup>e</sup>	ND <sup>f</sup>	[140]
phenol <sup>g</sup>	996		c1ccc(cc1)O	NB <sup>e</sup>	ND <sup>f</sup>	[140, 148]

<sup>a</sup>T=302K, with compounds from [148] measured in 50mM sodium acetate at pH 5.5 and thieno[2,3-c]pyridine measured at pH 6.8 in 50 mM potassium chloride and 38% (v/v) ethylene glycol; <sup>b</sup> part of the series of [129], so larger ligands in the series induce conformational change; <sup>c</sup> unknown due to solubility limitations, but likely binds strongly; <sup>d</sup> L99A sidechain undergoes rotation; <sup>e</sup> nonbinder; <sup>f</sup> not done; <sup>g</sup> included since it is a binder in the polar cavity; <sup>h</sup> PubChem compound ID.

multiple possible binding modes in relative free energy calculations [17], but this generates multiple results; determining the true relative binding free energy requires additional information [141]. Enhanced sampling approaches provide one possible solution to the binding mode problem. For example,  $\lambda$  or Hamiltonian exchange techniques can incorporate sampling on an artificial energy surface where the ligand does not interact with the protein, and thus can readily reorient. Thus, approaches employing this strategy can naturally sample multiple binding modes [68, 213].

While sidechain sampling has been a significant challenge, it is possible to use biased sampling techniques such as umbrella sampling to deliberately compute and include free energies of sampling slow sidechain rearrangements [138]. However, this is not a general solution, since it requires knowing what sidechains might rearrange on binding and then expending substantial computational power to map the free energy landscapes for these rearrangements. An apparently better general strategy is including sidechains in enhanced sampling regions selected for Hamiltonian exchange [95, 104] or REST2 [215], allowing sidechains to be alchemically softened or torsion barriers lowered (or both), to enhance sampling at alchemical intermediate states. Reduction of energy barriers at intermediate  $\lambda$  states in this scheme allows enhanced conformational sampling at these  $\lambda$  values. Then, with swaps between  $\lambda$  values, enhanced sidechain sampling at intermediate states can propagate to all states, improving conver-

gence [95, 215].

Larger protein conformational changes in lysozyme have received less attention, partly because until very recently they seemed to be a peculiar oddity only rarely observed; i.e., for ligands 4,5,6,7-tetrahydroindole and benzyl acetate in the polar site [17]. However, recent work noted above highlighted how a helix in the apolar cavity can open to accommodate larger ligands [129]. Timescales for this motion appear to be on the order of 50 ns, so it can pose sampling challenges, even for relative free energy calculations [117]. Including part of the protein in the enhanced sampling region via REST2 (described above) provides some benefits [117], but sampling these motions will likely prove a valuable test for enhanced sampling methods.

Accounting for water exchange into and out of these buried binding sites could also be a challenge in the polar binding site, as phenol binds with one ordered water [217]. However, to our knowledge, the simulation timescales for water sampling have not yet been examined, other than noting that water does not enter the polar binding site as ligands are removed [17]. In contrast, the apolar cavity is dry, both with and without a bound ligand, so water sampling is unlikely to be a challenge in this case.

TABLE VI: Proposed Lysozyme L99A/M102Q Set benchmark data

ligand	PC CID <sup>k</sup>	2D	SMILES	$\Delta G^a$ (kcal/mol)	PDB code	reference
toluene <sup>b</sup>	1140		Cc1ccccc1	-4.93	ND <sup>c</sup>	[217]
phenol	996		c1ccc(cc1)O	-5.24	1LI2 [217] [217]	
catechol <sup>h</sup>	289		c1ccc(c(c1)O)O	-4.16 ± 0.03	1XEP [81] [217]	
2-ethoxyphenol <sup>d</sup>	66755		CCOc1ccccc1O	-4.02 ± 0.03	3HU8 [17] [17]	
benzyl acetate <sup>e,f</sup>	8785		CC(=O)OCCc1ccccc1	-4.48 ± 0.16	3HUK [17] [17]	
4,5,6,7-tetrahydroindole <sup>f</sup>	57452536		c1c[nH]c2c1CCCC2	-4.61 ± 0.09	3HUA [17] [17]	
n-phenylglycinonitrile <sup>g</sup>	76372		c1ccccc1NCC#N	-5.52 ± 0.18	2RBN [17] [17]	
3-chlorophenol	7933		c1cc(cc(c1)Cl)O	-5.51	1LI3 [217] [217]	
2-methoxyphenol	460		COCc1ccccc1O	NB <sup>i</sup>	ND <sup>c</sup>	[17]
4-vinylpyridine	7502		C=Cc1ccncc1	NB <sup>i</sup>	ND <sup>c</sup>	[217]

<sup>a</sup>T=283K, with measurements done at pH 6.8 in 50 mM potassium phosphate, 200 mM potassium chloride buffer in the case of [17]; <sup>b</sup> included for symmetry with the L99A site since this (unlike phenol and benzene) binds in both; <sup>c</sup> not determined; <sup>d</sup> fails to make crystallographic hydrogen bond [17]; <sup>e</sup> multiple binding modes; <sup>f</sup> induces helix F motion; <sup>g</sup> induces flip of Val111 sidechain; <sup>h</sup> induces flip of Leu118 sidechain; <sup>j</sup> nonbinder; <sup>k</sup> PubChem compound ID.

### C. Protein-ligand benchmarks: the first bromodomain of the BRD4 protein

DLM: This organization is slightly inconsistent with the lysozyme organization, because this starts off with the biological relevance of bromodomains. I'm wondering if we should move the biology to a separate subsection and just jump in to what's relevant for modeling them? Specifically, the target audience I'm imagining is someone who just wants to benchmark methods and doesn't care about the biology of the system, just what is important for modeling it. Thoughts? PROBABLY that also means you want to lead with a summary of the most modeled binding systems (as in the lysozyme case) and what is known about the challenges there.

We extend our protein benchmarks to protein domains called bromodomains, which have recently been the topic of numerous studies in the search for high affinity ligands, using both computational [43, 46, 166, 167, 225, 227, 234] and experimental structure-based techniques [6, 32, 56, 59, 80, 168, 226, 232]. In living cells, bromodomains are

responsible for recognizing and binding to acetylated lysine residues present in the histone tails; these lysines serve as an epigenetic marker [31]. Bromodomains also bind a broad spectrum of small to medium-size molecules with micro and nanomolar affinities, and are a promising target for the treatment of conditions such as cancer and inflammation [58, 136, 158]. Bromodomains can be expressed, purified and studied as independent proteins, which facilitates the computational and experimental determination of ligand affinities. There are a total of 61 bromodomains identified in the human proteome, belonging to 46 different proteins [57]. They all have about 110 aminoacids in length and, despite having large sequence variations, share a common fold, consisting of four anti-parallel  $\alpha$ -helices (named  $\alpha$ Z,  $\alpha$ A,  $\alpha$ B, and  $\alpha$ C) folded into a left-handed bundle (Fig. 3A). The first two and last two helices are connected by the ZA and BC-loops, respectively [57]. These loops are more flexible and make part of the acetyl-lysine binding site, also displaying different lengths and sequences amongst the various bromodomains [195].

## 1. The first bromodomain of BRD4 and its ligands

DLM: In trying to organize like lysozyme, it seems like discussion of the specific benchmark proposed should get its own subsubsection header, so I proposed adding one above. Thoughts?

Our proposed bromodomain benchmark is the first bromodomain of the bromodomain-containing protein 4 (BRD4).

DLM: Seems like the below text mostly belongs in the bit on biological background?

... part of the BET (bromodomain and extra-terminal domain) family, which also includes the BRD2, BRD3, and BRDT proteins [57]. The BRD4 first bromodomain, or BRD4(1), is the most widely studied bromodomain in the BET family [55], with high-resolution cocrystal structures available for more than a hundred ligands, most of them accompanied by experimental affinities. Small molecule inhibitors of BRD4(1) have exceptional variety, including distinct groups such as triazoles, diazepines, acetyl-pyrroles, and isoxazoles [56, 73, 123, 226]. Due to the hydrophobic nature of the BRD4(1) binding site [55], all ligands are neutral, and many of them are also relatively rigid with the common presence of double and triple rings. This reduces the conformational space of the substrate in the bound and unbound states, providing quicker convergence, and partially avoiding symmetry issues that might appear for ligands with a large number of torsional degrees of freedom [137].

In contrast to T4 lysozyme, all BRD4(1) ligands bind to its surface [55, 56, 226], making this target more suitable for free energy calculations that rely on a physical pathway [85, 109, 155]. Additionally, the domain's folded state has shown remarkable stability over  $\mu$ s scale simulations [193, 195], which allows for relatively exhaustive sampling with less risk of unfolding or irreversible deformation happening on the protein structure. These characteristics, coupled with several careful free energy studies already conducted, make the BRD4(1) system a strong candidate for our first "hard" protein benchmark, but a few important issues have to be addressed in order to make this assertion. They involve the flexibility of the ZA-loop in the presence and absence of the substrate, and possible slow side-chain dihedral rotations near the binding site. Below we describe these challenges in more detail, and how they can be overcome.

DLM: In the sentences just prior, perhaps make it clearer what assertion/what issues. Do you mean something like "However, to serve as a hard benchmark, considerable care needs to be taken when dealing with several sampling challenges," or some such?

DLM: What do you think about making this subsection be "Computational challenges posed by the BRD4(1) benchmarks" and then have the two things below which you currently have as "subsubsections" use a smaller (paragraph?) label instead? This would be more consistent with the lysozyme material. Alternatively, I would also be happy with subsubsections called "BRD4(1) computational challenge: ZA loop flexibility" and "BRD4(1) computational challenge: sidechain sampling" or something similar. My issue is just that right now the organization seems fairly different from lysozyme and it's hard to keep track of what the subsubsection headers are supposed to mean.

## 2. Flexibility and transition of the ZA-loop

DLM: I have some TeX comments suggesting rephrasings in this paragraph

Simulations starting from the cocrystal structures of BRD4(1) bound to different ligands show that the complexes are very stable, with reported backbone RMSD values being less than 1.00 Å over simulations lasting up to 120ns [196]. The same behavior was reproduced in simulations over 300 ns long (Heinzelmann et al., unpublished results), with most of the fluctuations happening in the N and C-termini, which are far from the ligand binding site and can be disregarded. Even though the apo crystal structures of BRD4(1) have the same conformation as the complexes [57, 123], long simulations of this system using different force fields have shown considerable backbone RMSD values in the ZA-loop region [109, 195, 196]. However, instead of large random fluctuations, all cases show a sharp irreversible transition on this loop generally after 20 ns of simulations, suggesting an initial metastable state followed by stabilization of the protein backbone.

Further work found that the loop conformation seen in the *apo* structure is metastable and transitions to an open state (Fig. 3(B)) after around 50 ns [85]. The open state appears to be  $\sim$ 2.5 kcal/mol more favorable than the closed state, according to the free energy calculations performed using the Ambergff14SB protein force field and the TIP3P water model. This discrepancy between the crystal data and the simulations might arise from artifacts due to the simulation force field, or, on the other hand, be caused by crystal contacts involving loop residues and neighbouring molecules. This last possibility has been proposed before, when noting the inconsistency between the relatively uniform crystallographic B-factors and the high flexibility of the ZA-loop observed in simulations of the apo CREBBP bromodomain [193].

The free energy of the apo BRD4(1) closed-to-open conformational change is independent of the substrate [85], so it will not impact the ligands' *relative* binding free energies, as long as this transition is avoided




FIG. 3: (A) Crystal structure of BRD4(1) bound to the BZT-7 ligand (PDB ID: 3U5L), showing the four helices (blue), the ZA-loop (magenta) and the BC-loop (red). (B) Comparison of the 4LYI crystal structure in the closed state (blue), and the open state obtained after 350 ns of simulations of the same structure (yellow). The two hinges, Asp88 and Asp96, are shown in green. (C) The same structures of item B, but showing the side chains of the Tyr97, Tyr139 and Asn140 residues, which remain unaffected. (D) Time series of the Asn140  $\chi_2$  dihedral during 350 ns of simulations of the apo BRD4(1), showing frequent and reversible transitions.

during the calculations. This would be the case when performing small alchemical transformations on the substrate inside the binding pocket [216], since the BRD4(1) bound (closed) state will likely be preserved due to the presence of the ligand. For the calculation of the ligands *absolute* binding free energies, the conformational change of the apo BRD4(1) will influence computed binding free energies and has to be taken into account. As we explain below, the absolute binding free energies for the benchmark ligands can be computed either relative to the metastable *apo* closed state, consistent with the *apo* crystal structures of BRD4(1), or the *apo* open state, consistent with the Amberff14SB force-field, but computed values will be considerably different depending on this choice.

The ligand binding free energies relative to the metastable *apo* closed state of BRD4(1) are calculated by including a simple restraint-wall scheme on the Asp88  $\psi$  dihedral, as described in Ref. [85], so they are properly compared for each benchmark molecule. Alternatively, to determine the absolute ligand binding free energies relative to the *apo* open state, the free energy of the *apo* closed-to-open transition can also be determined. This transition appears to work through a double hinge mechanism centered on the Asp88 and Asp96 residues [85], and the free energy for the conformational change can be observed using a single reaction coordinate (the Asp88  $\psi$  dihedral), making the conformational change problem suitable for various enhanced sampling methods.

### 3. Possible side-chain rearrangements near the binding site

DLM: Some questions in the TeX on what you mean

Protein side-chain rearrangements pose another significant sampling challenge for BRD4(1). Even with the ZA-loop transition described above, 350ns simulations of the apo BRD4(1) did not exhibit the slow side-chain displacements of the conserved Tyr97 and Tyr139 residues (Fig. 3C), which are part of the acetyl-lysine binding site and are located on the ZA and BC-loops, respectively. The side-chain movements of these two residues were first observed on simulations of the apo CREBBP bromodomain [193, 195], with the Tyr1167 residue (equivalent to Tyr139 on BRD4(1)) adopting an outward conformation, followed by the occupation of the binding site by the side-chain of Tyr1125 (Tyr97 on BRD4(1)). On the other hand, as in Refs. [193, 195], rotations on the Asn140  $\chi_2$  dihedral frequently take place in simulations of the apo BRD4(1), but they are found to be reversible and happening in a nanosecond time scale (Fig. 3(D)). Still, we cannot neglect the possibility that slower side-chain transitions might still occur on BRD4(1) in the absence of the ligand, which would have to be accounted for if one is looking for gold standard results for this system.

### 4. Binding free energy calculations on BRD4(1)

DLM: For consistency with lysozyme organization, you probably want this section to be part of either the intro to bromodomains, or the section discussing sampling problems. For example, see the lysozyme section "The apolar and polar cavities and their ligands". ALSO, don't take a separate paragraph to describe each study. (We initially did that in the lysozyme and host-guest sections, but the paper gets way too long if this is done). Instead, focus just on the major take-aways. For example, accuracies of RMS error around 0.8 kcal/mol are possible; two studies basically agree on values of some of the ligands; the closed to open transition, etc. The idea is to tell people what they need to know (and give them references to read more) with as little extra text as possible.

Many studies have focused on the calculation of binding free energies of small molecules to BRD4(1), using a variety of methods such as alchemical transformations [2, 3], attach-pull-release (APR) [85], adaptive biasing potentials (ABP)[46], steered molecular dynamics (SMD) [155], as well as molecular mechanics combined with either Poisson-Boltzmann (MM-PBSA) [43, 196] or generalized Born (MM-GBSA) surface area [166]. The first two methods have provided the most rigorous calculations performed so far. They combine all-atom simulations with the application of restraints, in order to capture all the relevant degrees of freedom of the protein-

ligand system in both the bound and the unbound states.

Aldeghi et al. [2] have used alchemical calculations to determine the binding free energy of 11 ligands to the first BRD4 bromodomain, obtaining encouraging agreement with experimental values. When starting from the crystal structures of the complexes, the comparison to the experimental affinities yielded a Pearson's correlation coefficient of  $0.84 \pm 0.05$  and a root mean square error (RMSE) of  $0.8 \pm 0.2$  kcal/mol, with the 11 ligands spanning a  $\sim 4$  kcal/mol range. This rigorous alchemical approach was also able to determine the correct binding mode of the RVX-OH and RVX-208 ligands, when starting from multiple possibilities generated by docking. A subsequent study has extended it to other bromodomains [3], in order to test these calculations for both pose prediction and ligand selectivity. The binding free energies for RVX-OH and RVX-208 still showed good correlation with experiment, but the ones from bromosporine were less successful.

More recently, Heinzelmann et al. [85] used the attach-pull-release protocol to compute the binding free energies of seven ligands to BRD4(1), using different water models and ligand parameters. In contrast to alchemical transformations, APR relies on a physical path to pull the ligand from the binding site, by using umbrella sampling. Here two sets of binding free energies were calculated: one relative to the metastable apo closed state, and the other to the final apo open state. In both cases, the SPC/E water model combined with GAFF ligand parameters produced the best agreement with experimental values for the 7 ligands, with a Pearson's correlation coefficient of  $0.83 \pm 0.16$  for both final apo states, and RMSE values of  $1.42 \pm 0.29$  kcal/mol and  $1.29 \pm 0.36$  kcal/mol for the open and closed states, respectively.

In Ref. [85] there is also comparison between the APR and the alchemical approaches [2] for three of the ligands. Due to the shorter simulation times of 10ns per window, the closed to open transition was not observed in the alchemical calculations (personal communication by Biggin), therefore being relative to the metastable apo closed state of BRD4(1). Here excellent agreement is found for the three ligands, with the differences all within the associated uncertainties of the two methods. Even though the protein force fields are slightly different, Amber99SB-ILDN on Ref. [2] versus Amberff14SB on Ref. [85], this is an indication of the robustness of free energy techniques on this system if they are carried out rigorously.

### 5. Ligand benchmarks

## IV. FUTURE BENCHMARK SYSTEMS

Although the benchmark systems detailed above are useful, more systems are needed to expand the dataset, broaden the range of challenges, and bridge to biomedically relevant protein-ligand binding. The following subsections discuss additional systems that have already

been used to test computational methods and that may be suited for development as new benchmark systems in the near future.

### A. Host-Guest Systems

The cyclodextrins (CDs; Section III A) are a particularly promising source of additional host-guest benchmark sets. Cyclic glucose polymers, the CDs are produced from starch by an enzymatic process, and are available in gram quantities at low cost from multiple suppliers. Many experimental binding data, for varied guest molecules, are available for this class of host molecules, especially for 6-membered  $\alpha$ -CD and 7-membered  $\beta$ -CD, which both have adequate aqueous solubility. Indeed, a thorough review 1998 review tabulates hundreds of binding data [170], and many additional measurements have been published since then; e.g. references [24, 37, 38, 130, 174, 187, 222]. A number of these studies were done calorimetrically, and thus provide not only binding free energies but also binding enthalpies. Fewer data are available for 8-membered  $\gamma$ -CD, and the greater diameter of this host makes for a less well-defined and floppier binding cavity. Overall, the amount of existing binding data for CDs greatly exceeds what is currently available for CB7 and other cucurbiturils.

Structurally, the binding cavity of  $\beta$ -CD is about the same size as CB7 (Section IIIA 1), but the cyclodextrins are more flexible than CB7, as their glucose monomers are joined by one single bond, whereas CB7's glycouril monomers are joined by two single bonds. The CDs also appear easier to derivatize than the cucurbiturils. In particular, varied substituents may be appended by reactions involving secondary hydroxyls at the wide entry and primary hydroxyls at the narrow entry [48, 64, 98, 165, 199], with the caveat that generating pure products can be difficult, because there are so many hydroxyls that may be modified. Binding data on CD derivatives could be quite useful as a means of adding chemical diversity to host-guest benchmark sets, and such data are already available for some derivatives (see, e.g., [53, 170]).

The CDs are computationally tractable [11, 19, 26, 72, 86, 105, 124, 126, 179, 181, 219, 220, 233], and thus can be used for "hard" benchmark sets to test force fields (Section II A 1c). One complicating feature for calculations, relative to CB7, is that the two entryways to a CD are not equivalent, and asymmetric guest molecules may prefer to bind "head-in" or "head-out". As these two binding modes typically do not interchange on the microsecond timescale, they must be considered separately when one computes binding thermodynamics [86]. It is also worth noting that, because the CDs are glucose polymers, they may be best modeled with dedicated carbohydrate force fields [25, 84, 107, 224], rather than generalized small molecule force fields. A number of CD (and other host guest) binding systems are available for

download in electronic format at the BindingDB [79, 122] website ([www.bindingdb.org/bind/HostGuest.jsp](http://www.bindingdb.org/bind/HostGuest.jsp))

### B. Protein-Ligand Systems

On the order of a million experimental protein-ligand binding measurements are currently accessible through open-access databases, notably BindingDB [122], ChEMBL [12] and PubChem [106]. These databases can be valuable sources of, or at least starting points for, new protein-ligand benchmark datasets. In fact, automated procedures have already been used to extract about 700 downloadable validation sets ([www.bindingdb.org/validation\\_sets/index.jsp](http://www.bindingdb.org/validation_sets/index.jsp)), each comprising a congeneric series of ~10-50 ligands with binding data against a defined protein, and a cocrystal structure for at least one of the ligands in the series. However, there is still a need for a smaller collection of highly optimized benchmark sets as research foci for the computational chemistry community. Such sets should exemplify specific challenges not well covered by existing benchmark systems; be based upon high quality binding measurements for at least 20 ligands, measured by consistent procedures across all ligands; and include crystal structures for the apo-protein and cocrystal structures for multiple ligands. Analysis and extraction of such sets from the big databases is a promising future direction. Here, however, we take the less systematic but more expedient approach of considering several systems that have already proven themselves to be computationally tractable and informative.

#### 1. Constructed Binding Sites in Cytochrome C Peroxidase

Two artificial binding sites have been designed into the enzyme cytochrome C peroxidase (CCP): the "closed" site, created by the mutation W191G [60, 172]; and the "open" site mutant, created by supplementing mutation W191G with partial deletion of a loop, and thus opening the site to the outside of the protein [154, 172, 176]. As for the artificial binding cavities in T4 lysozyme (Section IIIB), the two CCP sites bind simple, fragment-like ligands with modest binding free energies (e.g., -3 to -7 kcal/mol for the open site [172]); discovery of new ligands is relatively straightforward [18, 172]; and new crystal structures can be obtained fairly readily. The protein has relatively modest size (around 280 residues) as in, for example, the 1KXM structure.

What is new is that the CCP binding sites contain an ASP which appears to be charged, at least in the presence of some ligands, as evidenced by observed interactions in structures, and by experiments where replacing the ASP with ASN abolishes binding of imidazoles, despite minimal changes to the binding site structure [61]. This side-chain interacts at short range with the ligands, which may be cationic or polar neutral compounds. As a

consequence, the CCP sites challenge the ability of computational methods to accurately account for strong electrostatic interactions in the low-dielectric interior of a protein [172]. Indeed, free energy calculations with two different force fields and distinct computational methods were found to overestimate the range of affinities, across a series of ligands, about three-fold, for the closed site [7, 8], and a similar pattern appears to hold for the open site [172]. Further analysis suggests that these overestimates stem from overestimated electrostatic interactions in these buried sites [172], perhaps because the force fields used did not account explicitly for electronic polarization. Additionally, the fact that different CCP ligands have different net charges may pose methodological challenges for some free energy techniques [173]. One modeling challenge is that CCP contains a heme, providing additional setup challenges (though since this is such an important cofactor, these may be worthwhile to face). In summary, these model CCP binding sites appear challenging yet tractable, and have already yielded insight regarding possible directions for force field improvements. Thus, they are good candidates to provide new benchmark sets in the near future.

## 2. Thrombin

Human thrombin, an enzyme of about 300 residues, is interesting both as a drug target related to blood coagulation and as a representative serine protease. Binding and structural data are available for a wide variety of ligands ([10, 164, 194, 205] and others), and have already been used as the basis for free energy simulations [20, 215, 216]. Some of the experimental binding data, obtained calorimetrically, highlight interesting trends, such as non-additivity (positive coupling) between substitutions at different locations on the chemical scaffolds of two compound series [10].

One computational study obtained relative free energies for two compound series that largely captured experimental trends and achieved an overall mean unsigned error of 0.74 kcal/mol over a range of roughly 5 kcal/mol. However, the accuracy of the results differed significantly between the two series [20]. Another relative binding free energy study for thrombin found that the results changed, depending on the initial conformation of the ligands, and showed that enhanced sampling techniques could reduce the dependence on starting conformation [215]. These prior studies suggest thrombin may be at a “sweet spot” for benchmark systems, where the system is relatively tractable, and encouraging results have been obtained, but where there are still clear challenges.

## 3. Bromodomain proteins

DLM: Germano, you will need to remove this section below and make sure everything relevant is incorporated into your earlier section

Bromodomains (BRDs) are a family of protein domains of about 100 residues that bind acetylated lysine residues at the surface of histones and thus read out epigenetic markers. Bromodomains are present in many human proteins, and are being explored as potential drug targets for diseases including cancer and atherosclerosis [2]. These compact domains can be expressed, purified and studied as independent proteins, and are associated with a growing body of small molecule binding data [6, 32, 58, 80, 88, 168, 227, 232], including some obtained by isothermal titration calorimetry [32, 58, 80, 88].

The small size of bromodomains, and the fact that their binding sites are relatively solvent-exposed, makes them particularly suitable for free energy simulations. One recent study, which used alchemical techniques to compute absolute binding free energies of 11 different ligands for bromodomain BRD4 [2], achieved a remarkable level of accuracy, RMS error  $0.8 \pm 0.2$  kcal/mol, for binding free energies spanning a range of 4 kcal/mol. Docking calculations included in the same study did not work as well. The compounds studied were diverse, and therefore not amenable to relative free energy methods in which one ligand is computationally converted into another.

An additional study applied absolute binding free energy calculations to compute the *selectivity* of three different bromodomain inhibitors across a variety of different bromodomain families. Affinities of two similar ligands for seven different bromodomains were computed with a mean unsigned error of just 0.81 kcal/mol and a Pearson correlation coefficient of 0.75. Additionally, the affinity of a broad spectrum bromodomain inhibitor was calculated for some 22 different bromodomains with more modest accuracy. Calculations also yielded insight into likely binding modes. The affinity data for this case is high quality, all from ITC, and a variety of crystal structures are available, making this a potentially exciting benchmark for absolute binding free energy calculations [3].

Overall, then, bromodomains appear to be class of systems that could yield relatively tractable and informative protein-ligand benchmark systems. One known challenge is that some ligands have multiple plausible binding modes [2, 3]. In addition, a diverse ligand series (or binding to different proteins in a family!) can pose severe challenges for relative free energy techniques, meaning that bromodomains may perhaps be appealing primarily as a benchmark for absolute calculations, though perhaps suitable series for relative calculations may also be available.

#### 4. Other protein-ligand systems

Several other systems may be of possible interest because of the wealth and quality of experimental data, the extent of prior computational work, or the combination of pharmaceutical relevance with important challenges. None of these seem to be well-characterized or well-studied enough yet to be benchmark systems, but they may be interesting choices for the future. The first system we would put in this category is trypsin, and especially binding of benzamidine and its derivatives. While trypsin has been the focus of several free energy studies [41, 96, 97, 201, 209] and the SAMPL3 challenge [156, 189], it also appears to be subject to extremely slow protein motions (on the tens of microsecond timescale) which are only beginning to be characterized [163]. As a consequence, short free energy calculations may appear to converge [96, 97, 201], but longer calculations can reveal a profound lack of convergence [163]. Therefore, trypsin may become a good benchmark for studying binding that is coupled with slow conformational dynamics; enhanced sampling methods and Markov state models [163] may be particularly helpful here.

HIV integrase is also of potential interest as a benchmark system. Indeed, blind predictions for a set of fragments binding to several sites formed part of the basis of the SAMPL4 challenge [142, 162]. Although the range of affinities in this set is modest (200 to 1450  $\mu\text{M}$  [162]), many crystal structures are available, as is a wealth of verified nonbinders [162]. One group actually did remarkably well using free energy calculations to recognize binding modes and predict nonbinders [67, 142]. Coupled with other HIV integrase data available in the literature and binding databases for larger ligands or other series, this may make this system attractive for future benchmarks.

The protein FKBP has also been the focus of several different free energy studies on the same series of ligands over the years [65, 66, 94, 114, 182, 212, 231]. However, in many cases, differences in calculated values between different studies – even with what appears to be the same force field and system preparation – are larger than differences relative to experiment [65, 94]. Some challenges are clear, such as conformational sampling for some of the larger ligands [182], and there have been some suggestions of force field issues and long equilibration times for the protein [66]. Perhaps this may be suitable as a benchmark system in the near-term as well.

A number of other proteins also have strong potential to generate useful benchmark sets. For example, free energy calculations have been carried out for influenza neuraminidase inhibitors [191] with some success [133], but other series include more complicated structure-activity relationships and are associated with protein loop motions that may be difficult to model [103]. Periplasmic oligopeptide binding protein A (OppA) binds a series of two to five-residue peptides, for which there exists a

large amount of calorimetric and crystallographic binding data [40, 190, 202], and the system appears challenging but potentially tractable for free energy calculations [128]. The JNK kinase may pose an interesting conformational sampling challenge, due to its slow interconversion between binding modes for some ligands [102]. And the ongoing series of Drug Design Data Resource (D3R) [71] blinded challenges may also be source of informative protein-ligand systems ([drugdesign-data.org/about/datasets](http://drugdesign-data.org/about/datasets)) that are familiar to the computational chemistry community. As noted above, however, many other protein-ligand binding systems have been characterized experimentally, and a systematic filtering would undoubtedly yield more benchmark candidates.

## V. HOW TO USE BENCHMARK SYSTEMS

Benchmark systems will have multiple uses, as discussed above, but not all benchmark systems can cover all uses. Some will be particularly valuable for testing accuracy relative to experiment. For this purpose, relatively large numbers of ligands are needed to afford meaningful statistics. Other benchmark systems will be more useful for testing sampling techniques, and still others will, at least initially, serve as test beds to determine the sensitivity of computational results to various factors.

In our view, benchmark systems will serve also to help design careful computational experiments. For example, researchers can test whether a particular method is sampling the motions which others have already shown to be important, or how the choice of starting conformation impacts the rate of convergence to a known, gold standard value for a particular force field and system composition. The availability of benchmark systems will also facilitate comparisons where only a single piece of a workflow is modified. For example, one may ask how results change if a different protonation state assignment tool is used to prepare a protein. Of course, such comparisons can already be done, but the results will be far more useful in the context of generally accepted and widely used test cases.

We hope that, ultimately, results from reliable “gold standard” binding free energy computations will be available for a set of benchmark systems. These would be from fully converged binding free energy calculations, and give correct results for a particular force field and system preparation, allowing quantitative comparison of the force field results with experiment. Such results will also facilitate a great deal of science on method efficiency, as new methods which purport to be more efficient could easily and *automatically* be run on a standard set of systems to see how much more efficient they are than the (perhaps brute-force) method which yielded the gold standard results. Thus, various enhanced sampling methods could easily be observed to have strengths and weaknesses on known problem classes. These systems will allow automated testing of the efficiency of new methods

on real-world problems.

## VI. WE NEED WORKFLOW SCIENCE

While the benchmark systems discussed here will already be useful, to fully realize their benefits a great deal of engineering needs to be done to facilitate workflow science. Currently, a wide variety of computational tools are available for different stages of the free energy calculation process, from system preparation (protonation state assignment, building in missing residues and loops, adding counterions, etc.) to force field assignment, to planning and conducting the calculations themselves (choice of method, simulation package, and so on). Often, each set of tools lives in its own ecosystem and is not designed to be easily interchangeable with tools from another ecosystem. This makes it very difficult to systematically compare methods that differ only in one respect; instead, one must adopt an entirely different toolset to change one aspect of a procedure. For example, swapping different tools for assigning protein protonation states could yield valuable insights into the relative merits of these tools and the importance of protonation at specific residues, but currently, this is, at best, an arduous task.

### A. Workflow automation is needed

At the most basic level, we need to allow calculations to be easily repeated on all of the benchmark systems via automated workflows. One should not have to become an expert in the systems being studied in order to be able to successfully apply calculations to them; inputs should be easily available and repeating calculations should become fully automated so that a new method can be tested by simply specifying the set of benchmarks to run on.

To achieve this, at least two major innovations are needed. First, we need automated workflows that can proceed from the specification of a system to target to yielding the desired results without human intervention. Second, we need a standard data structure for input to and output from these workflows so that people can easily obtain inputs for benchmark systems and only change the component they want to change (such as the force field or system preparation) and leave the other components unchanged so that, in an automated manner, they can focus their testing on only the components they want to test.

### B. Analysis automation will also be needed

At the most basic level, we can simply check whether we are getting the expected answer for each calculation performed, at least for systems where a gold standard result is available. However, this does not provide nearly enough insight, especially in cases of failure, where we

would like insight into *why* we failed. Are the relevant motions being sampled? Do we have the right protonation states and binding modes? Many other factors may need to be considered. We need ways to automatically check that we are sampling the right motions, identifying correct binding modes/conformations, and so on, without having to become experts on the specific systems examined. Probably we will need to define ways to automatically specify what order parameters should be monitored to assess for adequate sampling.

### C. Modularization will be key

To achieve these goals, researchers should develop or package tools so that they take a set of well specified inputs and provide well specified outputs in an interchangeable way. This may involve containerizing key pieces of workflows such as in Docker [47] or Singularity [110] containers, and developing standards as to what inputs and outputs are provided to each component of the workflow. Another key goal of modularization is to separate the *operator* from the *method*. Currently, binding calculations are most often done by a human expert, who makes a variety of decisions along the way (though Schrödinger’s workflow represents real progress toward automation [216]), making it difficult to separate the importance of human expertise from the merits of the methods employed. Containerizing and modularization will be key for this, allowing methods to be employed only in a well-defined way which is reproducible. It is this type of science – coupled with benchmark tests – which is needed to advance the field.

## VII. THE FUTURE OF THIS WORK

This work has so far presented a small group of benchmarks for binding free energy calculations, highlighted some of the ways in which they have already proven their utility, and has suggested some potential future benchmark systems. We hope that the community will become involved in identifying, characterizing, and helping to select additional benchmark systems, both from those proposed here as well as from systems which are currently being studied or which we have overlooked. We seek community input to help characterize, identify and share such systems. We also expect that there may be community interest in test systems specifically selected to challenge sampling algorithms, without reference to experimental data.

In order to provide for updates of this material as new benchmark systems are defined, and to enable community input into the process of choosing them, we have made the LaTeX source for this article on GitHub at <http://www.github.com/mobleylab/benchmarksets>, with each version having a permanent DOI assigned by Zenodo. We encourage use of the

GitHub issue tracker for discussion, comments, and proposed updates. We are incorporating new material via GitHub as one would for a coding project, and then making releases available both on GitHub and in more permanent form at eScholarship at <http://escholarship.org/uc/item/9p37m6bq>. Given substantial changes to this initial version of the paper, it may ultimately be appropriate to make it available as a “perpetual review” [143] via another forum allowing versioned updates of publications.

Ideally, we might also update this work in the future with results from “standard” calculations on the benchmark systems discussed here, along with links to code to allow reproduction of those calculations.

## VIII. CONCLUSIONS AND OUTLOOK

Binding free energy calculations are a promising tool for predicting and understanding molecular interactions and appear to have enough accuracy to provide substantial benefits in a pharmaceutical drug discovery context. However, progress is needed to improve these tools so that they can achieve their potential. To achieve steady progress, and to avoid potentially damaging cycles of enthusiasm and disillusionment, we need to understand and be open and honest about key challenges. Community adoption of well-chosen benchmark systems is vital for this, as it will allow researchers to rigorously test and compare methods, arrive at a shared understanding of problems, and measure progress on well-characterized yet challenging systems. It is also worth emphasizing the importance of sharing information about apparently well thought-out and even promising methods that do *not* work, rather than sharing only what does appear to work. Identifying and addressing failure cases and problems is critically important to advancing this technology, but failures can be harder to publish, and may even go unpublished, even though they serve a unique role in advancing the field. We therefore strongly encourage that such results be shared and welcomed by the research community. Potentially, the GitHub repository connected with this perpetual review paper could serve as a place to deposit input files and summary results of tests on these benchmark systems, with summary information perhaps being included in this work itself or top-

ical sub-reviews within the same repository. Host-guest input files are now available there.

Here, we have proposed several benchmark systems for binding free energy calculations. These embody a subset of the key challenges facing the field, and we plan to expand the set as consensus emerges. Hopefully, these systems will serve as challenging standard test cases for new methods, force fields, protocols, and workflows. Our desire is that these benchmarks will advance the science and technology of modeling and predicting molecular interactions, and that other researchers in the field will contribute to identifying new benchmark sets and updating the information provided about these informative systems.

## DISCLOSURE STATEMENT

D.L.M. is a member of the Scientific Advisory Board for OpenEye Scientific Software. M.K.G. is a cofounder and has equity interest in the company VeraChem LLC.

## ACKNOWLEDGMENTS

DLM appreciates financial support from the National Institutes of Health (NIH; 1R01GM108889-01) and the National Science Foundation (NSF; CHE 1352608). MKG thanks the NIH for partial support of this work through grants R01GM061300, R01GM070064 and U01GM111528. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or the NSF.

We also appreciate helpful discussions with a huge number of people in the field, including a wide variety of participants at recent meetings such as the 2016 Workshop on Free Energy Methods in Drug Discovery. Conversations with John Chodera (MSKCC), Chris Oostenbrink (BOKU), Julien Michel (Edinburgh), Robert Abel (Schrödinger), Bruce Gibb (Tulane), Matt Sullivan (Tulane), and Lyle Isaacs (Maryland) were particularly helpful. We thank David Slochower (UCSD) for a critical reading of the manuscript, and others listed on our GitHub repository for their contributions.

- 
- [1] R. Abel. Accelerating drug discovery with free energy calculations. [http://www.alchemy.org/wiki/images/e/eb/Vertex\\_talk\\_5\\_15\\_2016\\_clean3.pdf](http://www.alchemy.org/wiki/images/e/eb/Vertex_talk_5_15_2016_clean3.pdf), May 2016.
  - [2] M. Aldeghi, A. Heifetz, M. J. Bodkin, S. Knapp, and P. C. Biggin. Accurate calculation of the absolute free energy of binding for drug molecules. *Chem. Sci.*, 7(1):207–218, 2016.
  - [3] M. Aldeghi, A. Heifetz, M. J. Bodkin, S. Knapp, and P. C. Biggin. Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations. *J. Am. Chem. Soc.*, 139(2):946–957, Jan. 2017.
  - [4] M. P. Allen and D. J. Tildesley. *Computer Simulation of Liquids*. Oxford Science Publications. Oxford University Press, New York, NY, June 1989.
  - [5] K. I. Assaf and W. M. Nau. Cucurbiturils: From synthesis to high-affinity binding and catalysis. *Chem Soc Rev*, 44(2):394–418, Jan. 2015.

- [6] P. Bamborough, C.-w. Chung, R. C. Furze, P. Grandi, A.-M. Michon, R. J. Sheppard, H. Barnett, H. Diallo, D. P. Dixon, C. Douault, E. J. Jones, B. Karamshi, D. J. Mitchell, R. K. Prinjha, C. Rau, R. J. Watson, T. Werner, and E. H. Demont. Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. *J. Med. Chem.*, 58(15):6151–6178, Aug. 2015.
- [7] S. Banba and C. L. Brooks III. Free energy screening of small ligands binding to an artificial protein cavity. *The Journal of Chemical Physics*, 113(8):3423–3433, Aug. 2000.
- [8] S. Banba, Z. Guo, and C. L. Brooks III. Efficient Sampling of Ligand Orientations and Conformations in Free Energy Calculations Using the  $\lambda$ -Dynamics Method. *J. Phys. Chem. B*, 104(29):6903–6910, July 2000.
- [9] C. C. Bannan, K. H. Burley, M. Chiu, M. R. Shirts, M. K. Gilson, and D. L. Mobley. Blind prediction of cyclohexane–water distribution coefficients from the SAMPL5 challenge. *J Comput Aided Mol Des*, pages 1–18, Sept. 2016.
- [10] B. Baum, L. Muley, M. Smolinski, A. Heine, D. Hangauer, and G. Klebe. Non-additivity of Functional Group Contributions in Protein–Ligand Binding: A Comprehensive Study by Crystallography and Isothermal Titration Calorimetry. *Journal of Molecular Biology*, 397(4):1042–1054, Apr. 2010.
- [11] I. Beà, C. Jaime, and P. Kollman. Molecular recognition by  $\beta$ -cyclodextrin derivatives: Molecular dynamics, free-energy perturbation and molecular mechanics/Poisson–Boltzmann surface area goals and problems. *Theor Chem Acc*, 108(5):286–292, Nov. 2002.
- [12] A. P. Bento, A. Gaulton, A. Hersey, L. J. Bellis, J. Chambers, M. Davies, F. A. Krüger, Y. Light, L. Mak, S. McGlinchey, M. Nowotka, G. Papadatos, R. Santos, and J. P. Overington. The ChEMBL bioactivity database: An update. *Nucl Acids Res*, 42(D1):D1083–D1090, Jan. 2014.
- [13] S. Bhakat and P. Söderhjelm. Resolving the problem of trapped water in binding cavities: Prediction of host-guest binding free energies in the SAMPL5 challenge by funnel metadynamics. *J Comput Aided Mol Des*, 2016.
- [14] S. Boresch, F. Tettinger, M. Leitgeb, and M. Karplus. Absolute Binding Free Energies: A Quantitative Approach for Their Calculation. *The Journal of Physical Chemistry B*, 107(35):9535–9551, Sept. 2003.
- [15] S. Bosisio, A. S. J. S. Mey, and J. Michel. Blinded predictions of host-guest standard free energies of binding in the SAMPL5 challenge. *J Comput Aided Mol Des*, 2016.
- [16] G. Bouvignies, P. Vallurupalli, D. F. Hansen, B. E. Correia, O. Lange, A. Bah, R. M. Vernon, F. W. Dahlquist, D. Baker, and L. E. Kay. Solution structure of a minor and transiently formed state of a T4 lysozyme mutant. *Nature*, 477(7362):111–114, Sept. 2011.
- [17] S. E. Boyce, D. L. Mobley, G. J. Rocklin, A. P. Graves, K. A. Dill, and B. K. Shoichet. Predicting ligand binding affinity with alchemical free energy methods in a polar model binding site. *J. Mol. Biol.*, 394(4):747–763, Dec. 2009.
- [18] R. Brenk, S. W. Vetter, S. E. Boyce, D. B. Goodin, and B. K. Shoichet. Probing Molecular Docking in a Charged Model Binding Site. *Journal of Molecular Biology*, 357(5):1449–1470, Apr. 2006.
- [19] W. Cai, T. Sun, P. Liu, C. Chipot, and X. Shao. Inclusion Mechanism of Steroid Drugs into  $\beta$ -Cyclodextrins. Insights from Free Energy Calculations. *J. Phys. Chem. B*, 113(22):7836–7843, June 2009.
- [20] G. Calabò, C. J. Woods, F. Powlesland, A. S. J. S. Mey, A. J. Mulholland, and J. Michel. Elucidation of Nonadditive Effects in Protein–Ligand Binding Energies: Thrombin as a Case Study. *J. Phys. Chem. B*, June 2016.
- [21] L. Cao and L. Isaacs. Absolute and relative binding affinity of cucurbit[7]uril towards a series of cationic guests. *Supramolecular Chemistry*, 26(3-4):251–258, Mar. 2014.
- [22] L. Cao, M. Šekutor, P. Y. Zavalij, K. Mlinarić-Majerski, R. Glaser, and L. Isaacs. Cucurbit[7]uril-Guest Pair with an Attomolar Dissociation Constant. *Angew. Chem. Int. Ed.*, 53(4):988–993, Jan. 2014.
- [23] R. S. Carnegie, C. L. D. Gibb, and B. C. Gibb. Anion Complexation and The Hofmeister Effect. *Angew. Chem.*, 126(43):11682–11684, Oct. 2014.
- [24] J. Carrazana, A. Jover, F. Meijide, V. H. Soto, and J. Vázquez Tato. Complexation of Adamantyl Compounds by  $\beta$ -Cyclodextrin and Monoaminoderivatives. *J. Phys. Chem. B*, 109(19):9719–9726, May 2005.
- [25] C. Cézard, X. Trivelli, F. Aubry, F. Djedaini-Pillard, and F.-Y. Dupradeau. Molecular dynamics studies of native and substituted cyclodextrins in different media: 1. Charge derivation and force field performances. *Physical Chemistry Chemical Physics*, 13(33):15103–15121, 2011.
- [26] W. Chen, C.-E. Chang, and M. K. Gilson. Calculation of Cyclodextrin Binding Affinities: Energy, Entropy, and Implications for Drug Design. *Biophysical Journal*, 87(5):3035–3049, Nov. 2004.
- [27] J. D. Chodera, D. L. Mobley, M. R. Shirts, R. W. Dixon, K. Branson, and V. S. Pande. Alchemical free energy methods for drug discovery: Progress and challenges. *Curr Opin Struct Biol*, 21(2):150–160, Feb. 2011.
- [28] C. D. Christ. Binding affinity prediction from molecular simulations: A new standard method in structure-based drug design? [dx.doi.org/10.7490/f1000research.1112651.1](https://doi.org/10.7490/f1000research.1112651.1), May 2016.
- [29] C. D. Christ and T. Fox. Accuracy Assessment and Automation of Free Energy Calculations for Drug Design. *J. Chem. Inf. Model.*, 54(1):108–120, Jan. 2014.
- [30] C. D. Christ, A. E. Mark, and W. F. van Gunsteren. Basic ingredients of free energy calculations: A review. *J. Comput. Chem.*, 31(8):1569–1582, June 2010.
- [31] C.-w. Chung. *Progress in Medicinal Chemistry*, volume 51. Elsevier, Cambridge, MA, 2012.
- [32] C.-w. Chung, H. Coste, J. H. White, O. Mirquet, J. Wilde, R. L. Gosmini, C. Delves, S. M. Magny, R. Woodward, S. A. Hughes, E. V. Bourquier, H. Flynn, A. M. Bouillot, P. Bamborough, J.-M. G. Brusq, F. J. Gellibert, E. J. Jones, A. M. Riou, P. Homes, S. L. Martin, I. J. Uings, J. Toum, C. A. Clément, A.-B. Boullay, R. L. Grimley, F. M. Blandel, R. K. Prinjha, K. Lee, J. Kirillovsky, and E. Nicodeme. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. *J. Med. Chem.*, 54(11):3827–3838, June 2011.
- [33] D. J. Cole, J. Tirado-Rives, and W. L. Jorgensen. Molecular dynamics and Monte Carlo simulations for protein–ligand binding and inhibitor design. *Biochim-*

- ica et Biophysica Acta (BBA) - General Subjects*, 1850(5):966–971, May 2015.
- [34] M. D. Collins, M. L. Quillin, G. Hummer, B. W. Matthews, and S. M. Gruner. Structural Rigidity of a Large Cavity-containing Protein Revealed by High-pressure Crystallography. *Journal of Molecular Biology*, 367(3):752–763, Mar. 2007.
- [35] J. Comer, K. Schulten, and C. Chipot. Calculation of Lipid-Bilayer Permeabilities Using an Average Force. *J. Chem. Theory Comput.*, 10(2):554–564, Feb. 2014.
- [36] H. Cong, X. L. Ni, X. Xiao, Y. Huang, Q.-J. Zhu, S.-F. Xue, Z. Tao, L. F. Lindoy, and G. Wei. Synthesis and separation of cucurbit[n]urils and their derivatives. *Org. Biomol. Chem.*, 14(19):4335–4364, May 2016.
- [37] K. A. Connors. The Stability of Cyclodextrin Complexes in Solution. *Chem. Rev.*, 97(5):1325–1358, Aug. 1997.
- [38] E. S. Cotner and P. J. Smith. Phosphotyrosine Binding by Ammonium- and Guanidinium-Modified Cyclodextrins. *J. Org. Chem.*, 63(5):1737–1739, Mar. 1998.
- [39] G. Cui. Affinity Predictions with FEP+: A Different Perspective on Performance and Utility. [dx.doi.org/10.7490/f1000research.1112773.1](https://dx.doi.org/10.7490/f1000research.1112773.1), May 2016.
- [40] T. G. Davies, R. E. Hubbard, and J. R. Tame. Relating structure to thermodynamics: The crystal structures and binding affinity of eight OppA-peptide complexes. *Protein Science*, 8(7):1432–1444, Jan. 1999.
- [41] A. de Ruiter and C. Oostenbrink. Efficient and Accurate Free Energy Calculations on Trypsin Inhibitors. *J. Chem. Theory Comput.*, 8(10):3686–3695, Oct. 2012.
- [42] A. de Ruiter and C. Oostenbrink. Protein-Ligand Binding from Distancefield Distances and Hamiltonian Replica Exchange Simulations. *J. Chem. Theory Comput.*, 9(2):883–892, Feb. 2013.
- [43] V. Deepak, B. Wang, D. Koot, A. Kasonga, X. X. Stander, M. Coetzee, and A. Stander. In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antosteoclastogenic activity. *Chem. Biol. Drug. Des.*, 90(1):97–111, Feb. 2017.
- [44] N. Deng, S. Forli, P. He, A. Perryman, L. Wickstrom, R. S. K. Vijayan, T. Tiefenbrunn, D. Stout, E. Gallicchio, A. J. Olson, and R. M. Levy. Distinguishing Binders from False Positives by Free Energy Calculations: Fragment Screening Against the Flap Site of HIV Protease. *J. Phys. Chem. B*, 119(3):976–988, Jan. 2015.
- [45] Y. Deng and B. Roux. Calculation of Standard Binding Free Energies: Aromatic Molecules in the T4 Lysozyme L99A Mutant. *Journal of Chemical Theory and Computation*, 2(5):1255–1273, Sept. 2006.
- [46] B. M. Dickson, P. W. de Waal, Z. H. Ramjan, H. E. Xu, and S. B. Rothbart. A fast, open source implementation of adaptive biasing potentials uncovers a ligand design strategy for the chromatin regulator BRD4. *J. Chem. Phys.*, 145:154113, Oct. 2016.
- [47] Docker Inc. What is Docker? <https://www.docker.com/what-docker>, 2015-05-14T16:17:40-07:00.
- [48] H. Dodziuk. *Cyclodextrins and Their Complexes: Chemistry, Analytical Methods, Applications*. John Wiley & Sons, 2006.
- [49] J. B. Dunbar, R. D. Smith, C.-Y. Yang, P. M.-U. Ung, K. W. Lexa, N. A. Khazanov, J. A. Stuckey, S. Wang, and H. A. Carlson. CSAR Benchmark Exercise of 2010: Selection of the Protein–Ligand Complexes. *J. Chem. Inf. Model.*, 51(9):2036–2046, Sept. 2011.
- [50] A. Eklund, T. E. Nichols, and H. Knutsson. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. *Proc. Natl. Acad. Sci. U.S.A.*, 113(28):7900–7905, July 2016.
- [51] A. E. Eriksson, W. A. Baase, J. A. Wozniak, and B. W. Matthews. A cavity-containing mutant of T4 lysozyme is stabilized by buried benzene. *Nature*, 355(6358):371–373, Jan. 1992.
- [52] J. Ewell, B. C. Gibb, and S. W. Rick. Water Inside a Hydrophobic Cavitand Molecule. *The Journal of Physical Chemistry B*, 112(33):10272–10279, Aug. 2008.
- [53] P.-A. Faugeras, B. Boëns, P.-H. Elchinger, F. Brouillette, D. Montplaisir, R. Zerrouki, and R. Lucas. When Cyclodextrins Meet Click Chemistry. *Eur. J. Org. Chem.*, 2012(22):4087–4105, Aug. 2012.
- [54] A. T. Fenley, N. M. Henriksen, H. S. Muddana, and M. K. Gilson. Bridging Calorimetry and Simulation through Precise Calculations of Cucurbituril–Guest Binding Enthalpies. *Journal of Chemical Theory and Computation*, 10(9):4069–4078, Sept. 2014.
- [55] P. Filippakopoulos and S. Knapp. Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat. Rev. Drug Discov.*, 13:337–356, May 2014.
- [56] P. Filippakopoulos, S. Picaud, O. Fedorov, M. Keller, M. Wrobel, O. Morgenstern, F. Bracher, and S. Knapp. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the bet family. *Bioorg. Med. Chem.*, 20(6):1878–1886, Mar. 2012.
- [57] P. Filippakopoulos, S. Picaud, M. Mangos, T. Keates, J.-P. Lambert, D. Barsyte-Lovejoy, I. Felletar, R. Volkmer, S. Muller, T. Pawson, A.-C. Gingras, C. H. Arrowsmith, and S. Knapp. Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell*, 149(1):214–231, Mar. 2012.
- [58] P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp, and J. E. Bradner. Selective inhibition of BET bromodomains. *Nature*, 468(7327):1067–1073, Dec. 2010.
- [59] P. V. Fish, P. Filippakopoulos, G. Bish, P. E. Brennan, M. E. Bunnage, A. S. Cook, O. Federov, B. S. Gerstenberger, H. Jones, S. Knapp, B. Marsden, K. Nocka, D. R. Owen, M. Philpott, S. Picaud, M. J. Primiano, M. J. Ralph, N. Sciammetta, and J. D. Trzupek. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. *J. Med. Chem.*, 55(22):9831–9837, Oct. 2012.
- [60] M. M. Fitzgerald, R. A. Musah, D. E. McRee, and D. B. Goodin. A ligand-gated, hinged loop rearrangement opens a channel to a buried artificial protein cavity. *Nat Struct Mol Biol*, 3(7):626–631, July 1996.
- [61] M. M. Fitzgerald, M. L. Trester, G. M. Jensen, D. E. Mcree, and D. B. Goodin. The role of aspartate-235 in the binding of cations to an artificial cavity at the radical site of cytochrome c peroxidase. *Protein Science*, 4(9):1844–1850, Sept. 1995.
- [62] H. Flyvbjerg and H. G. Petersen. Error estimates on averages of correlated data. *The Journal of Chemical Physics*, 91(1):461, July 1989.

- [63] W. A. Freeman, W. L. Mock, and N. Y. Shih. Cucurbituril. *J. Am. Chem. Soc.*, 103(24):7367–7368, Dec. 1981.
- [64] K.-H. Frömming and J. Szejtli. Cyclodextrin Derivatives. In *Cyclodextrins in Pharmacy*, pages 19–32. 1994.
- [65] H. Fujitani, Y. Tanida, M. Ito, G. Jayachandran, C. D. Snow, M. R. Shirts, E. J. Sorin, and V. S. Pande. Direct calculation of the binding free energies of FKBP ligands. *The Journal of Chemical Physics*, 123(8):084108, Aug. 2005.
- [66] H. Fujitani, Y. Tanida, and A. Matsuura. Massively parallel computation of absolute binding free energy with well-equilibrated states. *Phys. Rev. E*, 79(2):021914, Feb. 2009.
- [67] E. Gallicchio, N. Deng, P. He, L. Wickstrom, A. L. Perryman, D. N. Santiago, S. Forli, A. J. Olson, and R. M. Levy. Virtual screening of integrase inhibitors by large scale binding free energy calculations: The SAMPL4 challenge. *J Comput Aided Mol Des*, 28(4):475–490, Feb. 2014.
- [68] E. Gallicchio, M. Lapelosa, and R. M. Levy. Binding Energy Distribution Analysis Method (BEDAM) for Estimation of Protein-Ligand Binding Affinities. *Journal of Chemical Theory and Computation*, 6(9):2961–2977, Sept. 2010.
- [69] H. Gan, C. J. Benjamin, and B. C. Gibb. Nonmonotonic Assembly of a Deep-Cavity Cavitand. *Journal of the American Chemical Society*, 133(13):4770–4773, Apr. 2011.
- [70] K. Gao, J. Yin, N. M. Henriksen, A. T. Fenley, and M. K. Gilson. Binding Enthalpy Calculations for a Neutral Host–Guest Pair Yield Widely Divergent Salt Effects across Water Models. *Journal of Chemical Theory and Computation*, 11(10):4555–4564, Oct. 2015.
- [71] S. Gathiaka, S. Liu, M. Chiu, H. Yang, J. A. Stuckey, Y. N. Kang, J. Delproposto, G. Kubish, J. B. Dunbar, H. A. Carlson, S. K. Burley, W. P. Walters, R. E. Amaro, V. A. Feher, and M. K. Gilson. D3R grand challenge 2015: Evaluation of protein–ligand pose and affinity predictions. *J Comput Aided Mol Des*, 30(9):651–668, Sept. 2016.
- [72] J. Gebhardt and N. Hansen. Calculation of binding affinities for linear alcohols to  $\alpha$ -cyclodextrin by twin-system enveloping distribution sampling simulations. *Fluid Phase Equilibria*, 422:1–17, Aug. 2016.
- [73] V. S. Gehling, M. C. Hewitt, R. G. Vaswani, Y. Leblanc, A. Cote, C. G. Nasveschuk, A. M. Taylor, J.-C. Harrange, J. E. Audia, E. Pardo, S. Joshi, P. Sandy, J. A. Mertz, R. J. Sims III, L. Bergeron, B. M. Bryant, S. Bellon, F. Poy, H. Jayaram, R. Sankaranarayanan, S. Yellapantula, N. B. Srinivasamurthy, S. Birudukota, and B. K. Albrecht. Discovery, design, and optimization of isoxazole azepine BET inhibitors. *ACS Med. Chem. Lett.*, 4(9):835–840, July 2013.
- [74] C. L. D. Gibb and B. C. Gibb. Well-Defined, Organic Nanoenvironments in Water: The Hydrophobic Effect Drives a Capsular Assembly. *J. Am. Chem. Soc.*, 126(37):11408–11409, Sept. 2004.
- [75] C. L. D. Gibb and B. C. Gibb. Guests of differing polarities provide insight into structural requirements for templates of water-soluble nano-capsules. *Tetrahedron*, 65(35):7240–7248, Aug. 2009.
- [76] C. L. D. Gibb and B. C. Gibb. Anion Binding to Hydrophobic Concavity Is Central to the Salting-in Effects of Hofmeister Chaotropes. *Journal of the American Chemical Society*, 133(19):7344–7347, May 2011.
- [77] C. L. D. Gibb and B. C. Gibb. Binding of cyclic carboxylates to octa-acid deep-cavity cavitand. *J Comput Aided Mol Des*, 28(4):319–325, Nov. 2013.
- [78] M. K. Gilson, J. A. Given, B. L. Bush, and J. A. McCammon. The statistical-thermodynamic basis for computation of binding affinities: A critical review. *Biophys J*, 72(3):1047–1069, Mar. 1997.
- [79] M. K. Gilson, T. Liu, M. Baitaluk, G. Nicola, L. Hwang, and J. Chong. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. *Nucl. Acids Res.*, 44(D1):D1045–D1053, Apr. 2016.
- [80] R. Gosmini, V. L. Nguyen, J. Toum, C. Simon, J.-M. G. Brusq, G. Krysa, O. Mirguet, A. M. Riou-Eymard, E. V. Boursier, L. Trottet, P. Bamforth, H. Clark, C.-w. Chung, L. Cutler, E. H. Demont, R. Kaur, A. J. Lewis, M. B. Schilling, P. E. Soden, S. Taylor, A. L. Walker, M. D. Walker, R. K. Prinjha, and E. Nicodème. The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor. *J. Med. Chem.*, 57(19):8111–8131, Oct. 2014.
- [81] A. P. Graves, R. Brenk, and B. K. Shoichet. Decoys for Docking. *Journal of Medicinal Chemistry*, 48(11):3714–3728, June 2005.
- [82] A. P. Graves, D. M. Shivakumar, S. E. Boyce, M. P. Jacobson, D. A. Case, and B. K. Shoichet. Rescoring Docking Hit Lists for Model Cavity Sites: Predictions and Experimental Testing. *Journal of Molecular Biology*, 377(3):914–934, Mar. 2008.
- [83] J. C. Gumbart, B. Roux, and C. Chipot. Standard Binding Free Energies from Computer Simulations: What Is the Best Strategy? *J. Chem. Theory Comput.*, 9(1):794–802, Jan. 2013.
- [84] O. Guvench, S. S. Mallajosyula, E. P. Raman, E. Hatcher, K. Vanommeslaeghe, T. J. Foster, F. W. Jamison, and A. D. MacKerell. CHARMM Additive All-Atom Force Field for Carbohydrate Derivatives and Its Utility in Polysaccharide and Carbohydrate–Protein Modeling. *J. Chem. Theory Comput.*, 7(10):3162–3180, Oct. 2011.
- [85] G. Heinzelmann, N. M. Henriksen, and M. K. Gilson. Attach-pull-release calculations of ligand binding and conformational changes on the first BRD4 bromodomain. *J. Chem. Theory Comput.*, ASAP, May 2017.
- [86] N. M. Henriksen, A. T. Fenley, and M. K. Gilson. Computational Calorimetry: High-Precision Calculation of Host–Guest Binding Thermodynamics. *Journal of Chemical Theory and Computation*, 11(9):4377–4394, Sept. 2015.
- [87] J. Hermans and S. Subramaniam. The free energy of xenon binding to myoglobin from molecular dynamics simulation. *Isr. J. Chem.*, 27:225–227, Jan. 1986.
- [88] D. S. Hewings, T. P. C. Rooney, L. E. Jennings, D. A. Hay, C. J. Schofield, P. E. Brennan, S. Knapp, and S. J. Conway. Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions. *J. Med. Chem.*, 55(22):9393–9413, Nov. 2012.
- [89] M. B. Hillyer, C. L. D. Gibb, P. Sokkalingam, J. H. Jordan, S. E. Ioup, and B. C. Gibb. Synthesis of Water-Soluble Deep-Cavity Cavitands. *Org. Lett.*,

- 18(16):4048–4051, Aug. 2016.
- [90] N. Homeyer, F. Stoll, A. Hillisch, and H. Gohlke. Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context. *J. Chem. Theory Comput.*, 10(8):3331–3344, Aug. 2014.
- [91] Y.-W. Hsiao and P. Söderhjelm. Prediction of SAMPL4 host–guest binding affinities using funnel metadynamics. *J. Comput. Aided Mol. Des.*, 28(4):443–454, Feb. 2014.
- [92] L. Isaacs. Cucurbit[n]urils: From mechanism to structure and function. *Chem. Commun.*, (6):619–629, 2009.
- [93] L. Isaacs. Personal communication, Sept. 2016.
- [94] G. Jayachandran, M. R. Shirts, S. Park, and V. S. Pande. Parallelized-over-parts computation of absolute binding free energy with docking and molecular dynamics. *The Journal of Chemical Physics*, 125(8):084901, Aug. 2006.
- [95] W. Jiang and B. Roux. Free Energy Perturbation Hamiltonian Replica-Exchange Molecular Dynamics (FEP/H-REMD) for Absolute Ligand Binding Free Energy Calculations. *Journal of Chemical Theory and Computation*, 6(9):2559–2565, Sept. 2010.
- [96] D. Jiao, P. A. Golubkov, T. A. Darden, and P. Ren. Calculation of protein–ligand binding free energy by using a polarizable potential. *PNAS*, 105(17):6290–6295, Apr. 2008.
- [97] D. Jiao, J. Zhang, R. E. Duke, G. Li, M. J. Schnieders, and P. Ren. Trypsin-ligand binding free energies from explicit and implicit solvent simulations with polarizable potential. *J. Comput. Chem.*, 30(11):1701–1711, Aug. 2009.
- [98] Jindřich and I. Tišlerová. Simple Preparation of 3I-O-Substituted  $\beta$ -Cyclodextrin Derivatives Using Cinnamyl Bromide. *J. Org. Chem.*, 70(22):9054–9055, Oct. 2005.
- [99] W. L. Jorgensen. Quantum and statistical mechanical studies of liquids. 12. Simulation of liquid ethanol including internal rotation. *Journal of the American Chemical Society*, 103(2):345–350, Jan. 1981.
- [100] W. L. Jorgensen, J. K. Buckner, S. Boudon, and J. Tirado-Rives. Efficient computation of absolute free energies of binding by computer simulations. Application to the methane dimer in water. *The Journal of Chemical Physics*, 89(6):3742–3746, Sept. 1988.
- [101] M. Karplus and J. A. McCammon. Molecular dynamics simulations of biomolecules. *Nat Struct Mol Biol*, 9(9):646–652, Sept. 2002.
- [102] J. W. Kaus, E. Harder, T. Lin, R. Abel, J. A. McCammon, and L. Wang. How To Deal with Multiple Binding Poses in Alchemical Relative Protein–Ligand Binding Free Energy Calculations. *J. Chem. Theory Comput.*, 11(6):2670–2679, June 2015.
- [103] P. S. Kerry, S. Mohan, R. J. M. Russell, N. Bance, M. Niikura, and B. M. Pinto. Structural basis for a class of nanomolar influenza A neuraminidase inhibitors. *Sci Rep*, 3, Oct. 2013.
- [104] I. V. Khavrukskii and A. Wallqvist. Improved Binding Free Energy Predictions from Single-Reference Thermodynamic Integration Augmented with Hamiltonian Replica Exchange. *Journal of Chemical Theory and Computation*, 7(9):3001–3011, Sept. 2011.
- [105] W. Khuntawee, T. Rungrotmongkol, P. Wolschann, P. Pongsawasdi, N. Kungwan, H. Okumura, and S. Hannongbua. Conformation study of -cyclodextrin: Replica exchange molecular dynamics simulations. *Carbohydr Polymers*, 141:99–105, May 2016.
- [106] S. Kim, P. A. Thiessen, E. E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B. A. Shoemaker, J. Wang, B. Yu, J. Zhang, and S. H. Bryant. PubChem Substance and Compound databases. *Nucleic Acids Res.*, 44(D1):D1202–D1213, Jan. 2016.
- [107] K. N. Kirschner, A. B. Yongye, S. M. Tschampel, J. González-Outeiriño, C. R. Daniels, B. L. Foley, and R. J. Woods. GLYCAM06: A generalizable biomolecular force field. Carbohydrates. *J. Comput. Chem.*, 29(4):622–655, Mar. 2008.
- [108] R. Kitahara and F. A. A. Mulder. Is pressure-induced signal loss in NMR spectra for the Leu99Ala cavity mutant of T4 lysozyme due to unfolding? *PNAS*, 112(9):E923–E923, Mar. 2015.
- [109] M. Kuang, J. Zhou, L. Wang, Z. Liu, J. Guo, and R. Wu. Binding kinetics versus affinities in BRD4 inhibition. *J. Chem. Inf. Model.*, 55(9):1926–1935, 2015.
- [110] G. M. Kurtzer. Singularity 2.1.2 - Linux application and environment containers for science, Dec. 2016.
- [111] C. T. Lee, J. Comer, C. Herndon, N. Leung, A. Pavlova, R. V. Swift, C. Tung, C. N. Rowley, R. E. Amaro, C. Chipot, Y. Wang, and J. C. Gumbart. Simulation-Based Approaches for Determining Membrane Permeability of Small Compounds. *J. Chem. Inf. Model.*, 56(4):721–733, Apr. 2016.
- [112] J. W. Lee, H. H. L. Lee, Y. H. Ko, K. Kim, and H. I. Kim. Deciphering the Specific High-Affinity Binding of Cucurbit[7]uril to Amino Acids in Water. *The Journal of Physical Chemistry B*, 119(13):4628–4636, Apr. 2015.
- [113] J. W. Lee, S. Samal, N. Selvapalam, H.-J. Kim, and K. Kim. Cucurbituril Homologues and Derivatives: New Opportunities in Supramolecular Chemistry. *Accounts of Chemical Research*, 36(8):621–630, 2003.
- [114] M. S. Lee and M. A. Olson. Calculation of Absolute Protein-Ligand Binding Affinity Using Path and Endpoint Approaches. *Biophysical Journal*, 90(3):864–877, Feb. 2006.
- [115] G. Leonis, T. Steinbrecher, and M. G. Papadopoulos. A Contribution to the Drug Resistance Mechanism of Darunavir, Amprenavir, Indinavir, and Saquinavir Complexes with HIV-1 Protease Due to Flap Mutation I50V: A Systematic MM-PBSA and Thermodynamic Integration Study. *J. Chem. Inf. Model.*, 53(8):2141–2153, Aug. 2013.
- [116] M. T. Lerch, C. J. López, Z. Yang, M. J. Kreitman, J. Horwitz, and W. L. Hubbell. Structure-relaxation mechanism for the response of T4 lysozyme cavity mutants to hydrostatic pressure. *PNAS*, 112(19):E2437–E2446, Dec. 2015.
- [117] N. M. Lim, L. Wang, R. Abel, and D. L. Mobley. Sensitivity in binding free energies due to protein reorganization. *Journal of Chemical Theory and Computation*, 12(9):4620–4631, July 2016.
- [118] Y.-L. Lin, A. Aleksandrov, T. Simonson, and B. Roux. An Overview of Electrostatic Free Energy Computations for Solutions and Proteins. *J. Chem. Theory Comput.*, 10(7):2690–2709, July 2014.
- [119] S. Liu, S. Cao, K. Hoang, K. L. Young, A. S. Paluch, and D. L. Mobley. Using MD Simulations To Calculate How Solvents Modulate Solubility. *Journal of Chemical Theory and Computation*, 12(4):1930–1941, Feb. 2016.
- [120] S. Liu, C. Ruspic, P. Mukhopadhyay, S. Chakrabarti, P. Y. Zavalij, and L. Isaacs. The Cucurbit[n]uril Family:

- Prime Components for Self-Sorting Systems. *Journal of the American Chemical Society*, 127(45):15959–15967, Nov. 2005.
- [121] S. Liu, Y. Wu, T. Lin, R. Abel, J. P. Redmann, C. M. Summa, V. R. Jaber, N. M. Lim, and D. L. Mobley. Lead optimization mapper: Automating free energy calculations for lead optimization. *J Comput Aided Mol Des*, 27(9):755–770, Sept. 2013.
- [122] T. Liu, Y. Lin, X. Wen, R. N. Jorissen, and M. K. Gilson. BindingDB: A web-accessible database of experimentally determined protein–ligand binding affinities. *Nucl. Acids Res.*, 35(suppl 1):D198–D201, Jan. 2007.
- [123] X. Lucas, D. Wohlwend, M. Hugle, K. Schmidtkunz, S. Gerhardt, R. Schule, M. Jung, O. Einsle, and S. Guntner. 4-Acyl pyrroles: Mimicking acetylated lysines in histone code reading. *Angew. Chem. Int. Ed.*, 52(52):14055–14059, Dec. 2013.
- [124] V. Luzhkov and J. Åqvist. Free-energy perturbation calculations of binding and transition-state energies: Hydrolysis of phenyl esters by  $\beta$ -cyclodextrin. *Chemical Physics Letters*, 302(3–4):267–272, Mar. 1999.
- [125] A. Maeno, D. Sindhikara, F. Hirata, R. Otten, F. W. Dahlquist, S. Yokoyama, K. Akasaka, F. A. A. Mulder, and R. Kitahara. Cavity as a Source of Conformational Fluctuation and High-Energy State: High-Pressure NMR Study of a Cavity-Enlarged Mutant of T4Lysozyme. *Biophysical Journal*, 108(1):133–145, Jan. 2015.
- [126] A. E. Mark, S. P. van Helden, P. E. Smith, L. H. M. Janssen, and W. F. van Gunsteren. Convergence Properties of Free Energy Calculations:  $\alpha$ -Cyclodextrin Complexes as a Case Study. *J. Am. Chem. Soc.*, 116(14):6293–6302, July 1994.
- [127] C. Márquez, R. R. Hudgins, and W. M. Nau. Mechanism of Host-Guest Complexation by Cucurbituril. *J. Am. Chem. Soc.*, 126(18):5806–5816, May 2004.
- [128] M. Maurer, S. B. A. de Beer, and C. Oostenbrink. Calculation of Relative Binding Free Energy in the Water-Filled Active Site of Oligopeptide-Binding Protein A. *Molecules*, 21(4):499, Apr. 2016.
- [129] M. Merski, M. Fischer, T. E. Balias, O. Eidam, and B. K. Shoichet. Homologous ligands accommodated by discrete conformations of a buried cavity. *PNAS*, 112(16):5039–5044, Apr. 2015.
- [130] M. Mic, A. Piřnáu, M. Bogdan, and I. Turcu. Inclusion complex of benzocaine and  $\beta$ -cyclodextrin:  $^1\text{H}$  NMR and isothermal titration calorimetry studies. In *AIP Conference Proceedings*, volume 1565, pages 63–66. AIP Publishing, Nov. 2013.
- [131] J. Michel and J. W. Essex. Hit Identification and Binding Mode Predictions by Rigorous Free Energy Simulations. *J. Med. Chem.*, 51(21):6654–6664, Nov. 2008.
- [132] J. Michel and J. W. Essex. Prediction of protein–ligand binding affinity by free energy simulations: Assumptions, pitfalls and expectations. *J Comput Aided Mol Des*, 24(8):639–658, May 2010.
- [133] J. Michel, M. L. Verdonk, and J. W. Essex. Protein-Ligand Binding Affinity Predictions by Implicit Solvent Simulations: A Tool for Lead Optimization? *J. Med. Chem.*, 49(25):7427–7439, Dec. 2006.
- [134] P. Mikulskis, D. Cioloboc, M. Andrejić, S. Khare, J. Brorsson, S. Genheden, R. A. Mata, P. Söderhjelm, and U. Ryde. Free-energy perturbation and quantum mechanical study of SAMPL4 octa-acid host–guest binding energies. *J Comput Aided Mol Des*, 28(4):375–400, Apr. 2014.
- [135] P. Mikulskis, S. Genheden, and U. Ryde. A Large-Scale Test of Free-Energy Simulation Estimates of Protein–Ligand Binding Affinities. *J. Chem. Inf. Model.*, 54(10):2794–2806, Oct. 2014.
- [136] O. Mirguet, R. Gosmini, J. Toum, C. A. Clement, M. Barnathan, J.-M. Brusq, J. E. Mordaunt, R. M. Grimes, M. Crowe, O. Pineau, M. Ajakane, A. Daugan, P. Jeffrey, L. Cutler, A. C. Haynes, N. N. Smithers, C.-w. Chung, P. Bamborough, I. J. Uings, A. Lewis, J. Witherington, N. Parr, R. K. Prinjha, and E. Nicodeme. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. *J. Med. Chem.*, 56(19):7501–7515, Sept. 2013.
- [137] D. L. Mobley, J. D. Chodera, and K. A. Dill. On the use of orientational restraints and symmetry corrections in alchemical free energy calculations. *J. Chem. Phys.*, 125:084902, Jan. 2006.
- [138] D. L. Mobley, J. D. Chodera, and K. A. Dill. Confine-and-Release Method: Obtaining Correct Binding Free Energies in the Presence of Protein Conformational Change. *Journal of Chemical Theory and Computation*, 3(4):1231–1235, July 2007.
- [139] D. L. Mobley, J. D. Chodera, L. Isaacs, and B. C. Gibb. Advancing predictive modeling through focused development of new systems to drive new modeling innovations. <http://doi.org/10.5281/zenodo.163963>, Oct. 2016.
- [140] D. L. Mobley, A. P. Graves, J. D. Chodera, A. C. McReynolds, B. K. Shoichet, and K. A. Dill. Predicting absolute ligand binding free energies to a simple model site. *J. Mol. Biol.*, 371(4):1118–1134, Aug. 2007.
- [141] D. L. Mobley and P. V. Klimovich. Perspective: Alchemical free energy calculations for drug discovery. *J. Chem. Phys.*, 137(23):230901, Jan. 2012.
- [142] D. L. Mobley, S. Liu, N. M. Lim, K. L. Wymer, A. L. Perryman, S. Forli, N. Deng, J. Su, K. Branson, and A. J. Olson. Blind prediction of HIV integrase binding from the SAMPL4 challenge. *J Comput Aided Mol Des*, 28(4):327–345, Mar. 2014.
- [143] D. L. Mobley and D. M. Zuckerman. A proposal for regularly updated review/survey articles: "Perpetual Reviews". *arXiv:1502.01329 [cs]*, Feb. 2015.
- [144] W. L. Mock and N. Y. Shih. Host-guest binding capacity of cucurbituril. *The Journal of Organic Chemistry*, 48(20):3618–3619, Oct. 1983.
- [145] S. Moghaddam, Y. Inoue, and M. K. Gilson. Host-guest complexes with protein-ligand-like affinities: Computational analysis and design. *Journal of the American Chemical Society*, 131(11):4012–4021, Mar. 2009.
- [146] S. Moghaddam, C. Yang, M. Rekharsky, Y. H. Ko, K. Kim, Y. Inoue, and M. K. Gilson. New Ultrahigh Affinity Host-Guest Complexes of Cucurbit[7]uril with Bicyclo[2.2.2]octane and Adamantane Guests: Thermodynamic Analysis and Evaluation of M2 Affinity Calculations. *Journal of the American Chemical Society*, 133(10):3570–3581, Mar. 2011.
- [147] J. I. Monroe and M. R. Shirts. Converging free energies of binding in cucurbit[7]uril and octa-acid host–guest systems from SAMPL4 using expanded ensemble simulations. *J Comput Aided Mol Des*, 28(4):401–415, Mar. 2014.

- [148] A. Morton, W. A. Baase, and B. W. Matthews. Energetic origins of specificity of ligand binding in an interior nonpolar cavity of T4 lysozyme. *Biochemistry*, 34(27):8564–8575, July 1995.
- [149] A. Morton and B. W. Matthews. Specificity of ligand binding in a buried nonpolar cavity of T4 lysozyme: Linkage of dynamics and structural plasticity. *Biochemistry*, 34(27):8576–8588, July 1995.
- [150] H. S. Muddana, A. T. Fenley, D. L. Mobley, and M. K. Gilson. The SAMPL4 host–guest blind prediction challenge: An overview. *J Comput Aided Mol Des*, 28(4):305–317, Mar. 2014.
- [151] H. S. Muddana and M. K. Gilson. Prediction of SAMPL3 host–guest binding affinities: Evaluating the accuracy of generalized force-fields. *J Comput Aided Mol Des*, 26(5):517–525, Jan. 2012.
- [152] H. S. Muddana, C. D. Varnado, C. W. Bielawski, A. R. Urbach, L. Isaacs, M. T. Geballe, and M. K. Gilson. Blind prediction of host–guest binding affinities: A new SAMPL3 challenge. *J Comput Aided Mol Des*, 26(5):475–487, Feb. 2012.
- [153] H. S. Muddana, J. Yin, N. V. Sapra, A. T. Fenley, and M. K. Gilson. Blind prediction of SAMPL4 cucurbit[7]uril binding affinities with the mining minima method. *J Comput Aided Mol Des*, 28(4):463–474, Feb. 2014.
- [154] R. A. Musah, G. M. Jensen, S. W. Bunte, R. J. Rosenfeld, and D. B. Goodin. Artificial protein cavities as specific ligand-binding templates: Characterization of an engineered heterocyclic cation-binding site that preserves the evolved specificity of the parent protein1. *Journal of Molecular Biology*, 315(4):845–857, Jan. 2002.
- [155] C. Muvva, E. R. A. Singam, S. S. Raman, and V. Subramanian. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. *Mol. Biosyst.*, 10(9):2384–2397, July 2014.
- [156] J. Newman, O. Dolezal, V. Fazio, T. Caradoc-Davies, and T. S. Peat. The DINGO dataset: A comprehensive set of data for the SAMPL challenge. *J Comput Aided Mol Des*, 26(5):497–503, Dec. 2011.
- [157] C. N. Nguyen, T. K. Young, and M. K. Gilson. Grid inhomogeneous solvation theory: Hydration structure and thermodynamics of the miniature receptor cucurbit[7]uril. *The Journal of Chemical Physics*, 137(4):044101, July 2012.
- [158] E. Nicodeme, K. L. Jeffrey, U. Schaefer, S. Beinke, S. Dewell, C.-w. Chung, R. Chandwani, I. Marazzi, P. Wilson, H. Coste, J. White, J. Kirillovsky, C. M. Rice, J. M. Lora, R. K. Prinjha, K. Lee, and A. Tarakhovsky. Suppression of inflammation by a synthetic histone mimic. *Nature*, 468(7327):1119–1123, Nov. 2010.
- [159] N. V. Nucci, B. Fuglestad, E. A. Athanasoula, and A. J. Wand. Role of cavities and hydration in the pressure unfolding of T4 lysozyme. *PNAS*, 111(38):13846–13851, Sept. 2014.
- [160] R. K. Pal, K. Haider, D. Kaur, W. Flynn, J. Xia, R. M. Levy, T. Taran, L. Wickstrom, T. Kurtzman, and E. Gallicchio. A combined treatment of hydration and dynamical effects for the modeling of host-guest binding thermodynamics: The SAMPL5 blinded challenge. *Journal of Computer-Aided Molecular Design*, 2016.
- [161] J. Park, I. Nessler, B. McClain, D. Macikenas, J. Baltrusaitis, and M. J. Schnieders. Absolute Organic Crystal Thermodynamics: Growth of the Asymmetric Unit into a Crystal via Alchemy. *J. Chem. Theory Comput.*, 10(7):2781–2791, July 2014.
- [162] T. S. Peat, O. Dolezal, J. Newman, D. Mobley, and J. J. Deadman. Interrogating HIV integrase for compounds that bind— a SAMPL challenge. *J Comput Aided Mol Des*, 28(4):347–362, Feb. 2014.
- [163] N. Plattner and F. Noé. Protein conformational plasticity and complex ligand-binding kinetics explored by atomistic simulations and Markov models. *Nature Communications*, 6:7653, July 2015.
- [164] S. Putta, G. A. Landrum, and J. E. Penzotti. Conformation Mining: An Algorithm for Finding Biologically Relevant Conformations. *J. Med. Chem.*, 48(9):3313–3318, May 2005.
- [165] Q. I. Qu, E. Tucker, and S. D. Christian. Sulfoalkyl Ether  $\beta$ -Cyclodextrin Derivatives: Synthesis and Characterizations. *Journal of Inclusion Phenomena*, 43(3–4):213–222, Aug. 2002.
- [166] U. Raj, H. Kumar, and P. K. Varadwaj. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors. *J. Biomol. Struct. Dyn.*, pages 1–12, Aug. 2016.
- [167] T. Ran, Z. Zhang, K. Liu, Y. Lu, H. Li, J. Xu, X. Xiong, Y. Zhang, A. Xu, S. Lu, H. Liu, T. Lu, and Y. Chen. Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation. *Mol. Biosyst.*, 11(5):1295–1304, May 2015.
- [168] X. Ran, Y. Zhao, L. Liu, L. Bai, C.-Y. Yang, B. Zhou, J. L. Meagher, K. Chinnaswamy, J. A. Stuckey, and S. Wang. Structure-Based Design of  $\gamma$ -Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. *J. Med. Chem.*, 58(12):4927–4939, June 2015.
- [169] M. M. Reif and C. Oostenbrink. Net charge changes in the calculation of relative ligand-binding free energies via classical atomistic molecular dynamics simulation. *J. Comput. Chem.*, 35(3):227–243, Jan. 2014.
- [170] M. V. Rekharsky and Y. Inoue. Complexation Thermodynamics of Cyclodextrins. *Chem. Rev.*, 98(5):1875–1918, July 1998.
- [171] M. V. Rekharsky, T. Mori, C. Yang, Y. H. Ko, N. Selvapalam, H. Kim, D. Sobransingh, A. E. Kaifer, S. Liu, L. Isaacs, W. Chen, S. Moghaddam, M. K. Gilson, K. Kim, and Y. Inoue. A synthetic host-guest system achieves avidin-biotin affinity by overcoming enthalpy–entropy compensation. *PNAS*, 104(52):20737–20742, Dec. 2007.
- [172] G. J. Rocklin, S. E. Boyce, M. Fischer, I. Fish, D. L. Mobley, B. K. Shoichet, and K. A. Dill. Blind Prediction of Charged Ligand Binding Affinities in a Model Binding Site. *J. Mol. Biol.*, 425(22):4569–4583, Nov. 2013.
- [173] G. J. Rocklin, D. L. Mobley, K. A. Dill, and P. H. Hünenberger. Calculating the binding free energies of charged species based on explicit-solvent simulations employing lattice-sum methods: An accurate correction scheme for electrostatic finite-size effects. *J. Chem. Phys.*, 139(18):184103, Jan. 2013.
- [174] A. I. Rodriguez-Perez, C. Rodriguez-Tenreiro, C. Alvarez-Lorenzo, P. Taboada, A. Concheiro, and J. J. Torres-Labandeira. Sertaconazole/hydroxypropyl- $\beta$ -cyclodextrin complexation: Isothermal titration calorimetry and solubility approaches. *J. Pharm. Sci.*, 95(8):1751–1762, Aug. 2006.

- [175] K. E. Rogers, J. M. Ortiz-Sánchez, R. Baron, M. Fajer, C. A. F. de Oliveira, and J. A. McCammon. On the Role of Dewetting Transitions in Host–Guest Binding Free Energy Calculations. *Journal of Chemical Theory and Computation*, 9(1):46–53, Jan. 2013.
- [176] R. J. Rosenfeld, A.-M. A. Hays, R. A. Musah, and D. B. Goodin. Excision of a proposed electron transfer pathway in cytochrome c peroxidase and its replacement by a ligand-binding channel. *Protein Science*, 11(5):1251–1259, May 2002.
- [177] M. J. Schnieders, J. Baltrusaitis, Y. Shi, G. Chattree, L. Zheng, W. Yang, and P. Ren. The Structure, Thermodynamics, and Solubility of Organic Crystals from Simulation with a Polarizable Force Field. *J. Chem. Theory Comput.*, 8(5):1721–1736, May 2012.
- [178] P. Schreiner. Theoretical prediction of affinities to cucurbiturils – the blind prediction hydrophobe challenge. <https://www.uni-giessen.de/fbz/fb08/dispersion/projects/HydrophobeChallenge>, 2016.
- [179] B. Sellner, G. Zifferer, A. Kornherr, D. Krois, and U. H. Brinker. Molecular Dynamics Simulations of  $\beta$ -Cyclodextrin-Aziadamantane Complexes in Water. *J. Phys. Chem. B*, 112(3):710–714, Jan. 2008.
- [180] B. Sherborne, V. Shanmugasundaram, A. C. Cheng, C. D. Christ, R. L. DesJarlais, J. S. Duca, R. A. Lewis, D. A. Loughney, E. S. Manas, G. B. McGaughey, C. E. Peishoff, and H. van Vlijmen. Collaborating to improve the use of free-energy and other quantitative methods in drug discovery. *J Comput Aided Mol Des*, 30(12):1139–1141, Dec. 2016.
- [181] M. Shi, C. Zhang, Y. Xie, and D. Xu. Stereoselective inclusion mechanism of ketoprofen into  $\beta$ -cyclodextrin: Insights from molecular dynamics simulations and free energy calculations. *Theor Chem Acc*, 133(10):1556, Oct. 2014.
- [182] M. R. Shirts. *Calculating Precise and Accurate Free Energies in Biomolecular Systems*. Stanford University, Stanford, CA, 2004.
- [183] M. R. Shirts and J. D. Chodera. Statistically optimal analysis of samples from multiple equilibrium states. *The Journal of Chemical Physics*, 129(12):124105, Sept. 2008.
- [184] M. R. Shirts, C. Klein, J. M. Swails, J. Yin, M. K. Gilson, D. L. Mobley, D. A. Case, and M. R. Shirts. Lessons learned from comparing molecular dynamics engines on the SAMPL5 dataset. *J Comput Aided Mol Des*, 2016.
- [185] M. R. Shirts and D. L. Mobley. An Introduction to Best Practices in Free Energy Calculations. In *Biomolecular Simulations*, volume 924. Methods in Molecular Biology, Jan. 2013.
- [186] M. R. Shirts, D. L. Mobley, and S. P. Brown. Free-energy calculations in structure-based drug design. In J. Merz, Kenneth M, D. Ringe, and C. H. Reynolds, editors, *Drug Design: Structure and Ligand-Based Approaches*. Cambridge University Press, Jan. 2010.
- [187] H.-J. Shu, C.-M. Zeng, C. Wang, D. F. Covey, C. F. Zorumski, and S. Mennerick. Cyclodextrins sequester neuroactive steroids and differentiate mechanisms that rate limit steroid actions. *British Journal of Pharmacology*, 150(2):164–175, Jan. 2007.
- [188] T. Simonson and B. Roux. Concepts and protocols for electrostatic free energies. *Molecular Simulation*, 42(13):1090–1101, Sept. 2016.
- [189] A. G. Skillman. SAMPL3: Blinded prediction of host–guest binding affinities, hydration free energies, and trypsin inhibitors. *J Comput Aided Mol Des*, 26(5):473–474, May 2012.
- [190] S. H. Sleigh, P. R. Seavers, A. J. Wilkinson, J. E. Ladbury, and J. R. H. Tame. Crystallographic and Calorimetric Analysis of Peptide Binding to OppA Protein. *Journal of Molecular Biology*, 291(2):393–415, Aug. 1999.
- [191] P. W. Smith, S. L. Sollis, P. D. Howes, P. C. Cherry, I. D. Starkey, K. N. Cobley, H. Weston, J. Scicinski, A. Merritt, A. Whittington, P. Wyatt, N. Taylor, D. Green, R. Bethell, S. Madar, R. J. Fenton, P. J. Morley, T. Pateman, and A. Beresford. Dihydropyran-carboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. 1. Discovery, Synthesis, Biological Activity, and Structure-Activity Relationships of 4-Guanidino- and 4-Amino-4H-pyran-6-carboxamides. *J. Med. Chem.*, 41(6):787–797, Mar. 1998.
- [192] P. Sokkalingam, J. Shrabeberg, S. W. Rick, and B. C. Gibb. Binding Hydrated Anions with Hydrophobic Pockets. *Journal of the American Chemical Society*, 138(1):48–51, Jan. 2016.
- [193] D. Spiliotopoulos and A. Caflisch. Molecular dynamics simulations of bromodomains reveal binding-site flexibility and multiple binding modes of the natural ligand acetyl-lysine. *Isr. J. Chem.*, 54(9):1084–1092, Aug. 2014.
- [194] P. Štefanič Anderluh, M. Anderluh, J. Ilaš, J. Mravljak, M. Sollner Dolenc, M. Stegnar, and D. Kikelj. Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic Activities. *J. Med. Chem.*, 48(9):3110–3113, May 2005.
- [195] S. Steiner, A. Magno, D. Huang, and A. Caflisch. Does bromodomain flexibility influence histone recognition? *FEBS Lett.*, 587(14):2158–2163, July 2013.
- [196] J. Su, X. Liu, S. Zhang, F. Yan, Q. Zhang, and J. Chen. A computational insight into binding modes of inhibitors XD29, XD35, and XD28 to bromodomain-containing protein 4 based on molecular dynamics simulations. *J. Biomol. Struct. Dyn.*, pages 1–13, May 2017.
- [197] M. R. Sullivan, P. Sokkalingam, T. Nguyen, J. P. Donahue, and B. C. Gibb. Binding of carboxylate and trimethylammonium salts to octa-acid and TEMOA deep-cavity cavitands. *J Comput Aided Mol Des*, pages 1–8, July 2016.
- [198] H. Sun, C. L. D. Gibb, and B. C. Gibb. Calorimetric Analysis of the 1:1 Complexes Formed between a Water-soluble Deep-cavity Cavitand, and Cyclic and Acyclic Carboxylic Acids. *Supramolecular Chemistry*, 20(1-2):141–147, Jan. 2008.
- [199] L. Szente and J. Szejtli. Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development. *Advanced Drug Delivery Reviews*, 36(1):17–28, Mar. 1999.
- [200] K. Tai. Conformational sampling for the impatient. *Biochemical Chemistry*, 107(3):213–220, Feb. 2004.
- [201] R. Talhout, A. Villa, A. E. Mark, and J. B. F. N. Engberts. Understanding Binding Affinity: A Combined Isothermal Titration Calorimetry/Molecular Dynamics Study of the Binding of a Series of Hydropho-

- bically Modified Benzamidinium Chloride Inhibitors to Trypsin. *J. Am. Chem. Soc.*, 125(35):10570–10579, Sept. 2003.
- [202] J. R. Tame, E. J. Dodson, G. Murshudov, C. F. Higgins, and A. J. Wilkinson. The crystal structures of the oligopeptide-binding protein OppA complexed with tripeptide and tetrapeptide ligands. *Structure*, 3(12):1395–1406, Dec. 1995.
- [203] B. L. Tembe and J. A. McCammon. Ligand Receptor Interactions. *Comput. Chem.*, 8(4):281–283, Jan. 1984.
- [204] F. Tofoleanu, J. Lee, F. C. Pickard IV., G. König, J. Huang, M. Baek, C. Seok, and B. R. Brooks. Absolute binding free energy calculations for octa-acids and guests. *J Comput. Aided Mol. Des.*, 2016.
- [205] H. Ueno, K. Yokota, J.-i. Hoshi, K. Yasue, M. Hayashi, I. Uchida, K. Aisaka, Y. Hase, S. Katoh, and H. Cho. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors. *Bioorganic & Medicinal Chemistry Letters*, 15(1):185–189, Jan. 2005.
- [206] C. Velez-Vega and M. K. Gilson. Force and Stress along Simulated Dissociation Pathways of Cucurbituril–Guest Systems. *J. Chem. Theory Comput.*, 8(3):966–976, Mar. 2012.
- [207] C. Velez-Vega and M. K. Gilson. Overcoming dissipation in the calculation of standard binding free energies by ligand extraction. *J. Comput. Chem.*, 34(27):2360–2371, Oct. 2013.
- [208] A. Verras. Free Energy Perturbation at Merck: Benchmarking against Faster Methods. [http://www.alchemy.org/wiki/images/c/c3/Vertex\\_FreeEnergyWorkshop2016\\_AV.pdf](http://www.alchemy.org/wiki/images/c/c3/Vertex_FreeEnergyWorkshop2016_AV.pdf), May 2016.
- [209] A. Villa, R. Zangi, G. Pieffet, and A. E. Mark. Sampling and convergence in free energy calculations of protein–ligand interactions: The binding of triphenoxypyridine derivatives to factor Xa and trypsin. *J Comput. Aided Mol. Des.*, 17(10):673–686, 2003.
- [210] B. Vinciguerra, P. Y. Zavalij, and L. Isaacs. Synthesis and Recognition Properties of Cucurbit[8]uril Derivatives. *Org. Lett.*, 17(20):5068–5071, Oct. 2015.
- [211] A. J. Wand and N. V. Nucci. Reply to Kitahara and Mulder: An ensemble view of protein stability best explains pressure effects in a T4 lysozyme cavity mutant. *PNAS*, 112(9):E924–E924, Mar. 2015.
- [212] J. Wang, Y. Deng, and B. Roux. Absolute Binding Free Energy Calculations Using Molecular Dynamics Simulations with Restraining Potentials. *Biophysical Journal*, 91(8):2798–2814, Oct. 2006.
- [213] K. Wang, J. D. Chodera, Y. Yang, and M. R. Shirts. Identifying ligand binding sites and poses using GPU-accelerated Hamiltonian replica exchange molecular dynamics. *J Comput. Aided Mol. Des.*, 27(12):989–1007, Dec. 2013.
- [214] K. Wang, P. Sokkalingam, and B. C. Gibb. ITC and NMR analysis of the encapsulation of fatty acids within a water-soluble cavitand and its dimeric capsule. *Supramolecular Chemistry*, 28(1–2):84–90, Feb. 2016.
- [215] L. Wang, B. J. Berne, and R. A. Friesner. On achieving high accuracy and reliability in the calculation of relative protein–ligand binding affinities. *PNAS*, 109(6):1937–1942, July 2012.
- [216] L. Wang, Y. Wu, Y. Deng, B. Kim, L. Pierce, G. Krilov, D. Lupyan, S. Robinson, M. K. Dahlgren, J. Greenwood, D. L. Romero, C. Masse, J. L. Knight, T. Steinbrecher, T. Beuming, W. Damm, E. Harder, W. Sher-
- man, M. Brewer, R. Wester, M. Murcko, L. Frye, R. Farid, T. Lin, D. L. Mobley, W. L. Jorgensen, B. J. Berne, R. A. Friesner, and R. Abel. Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field. *J Am Chem Soc*, 137(7):2695–2703, Feb. 2015.
- [217] B. Q. Wei, W. A. Baase, L. H. Weaver, B. W. Matthews, and B. K. Shoichet. A Model Binding Site for Testing Scoring Functions in Molecular Docking. *Journal of Molecular Biology*, 322(2):339–355, Sept. 2002.
- [218] B. Q. Wei, L. H. Weaver, A. M. Ferrari, B. W. Matthews, and B. K. Shoichet. Testing a Flexible-receptor Docking Algorithm in a Model Binding Site. *Journal of Molecular Biology*, 337(5):1161–1182, Apr. 2004.
- [219] L. Wickstrom, N. Deng, P. He, A. Mentes, C. Nguyen, M. K. Gilson, T. Kurtzman, E. Gallicchio, and R. M. Levy. Parameterization of an effective potential for protein–ligand binding from host–guest affinity data. *J. Mol. Recognit.*, 29(1):10–21, Jan. 2016.
- [220] L. Wickstrom, P. He, E. Gallicchio, and R. M. Levy. Large Scale Affinity Calculations of Cyclodextrin Host–Guest Complexes: Understanding the Role of Reorganization in the Molecular Recognition Process. *J. Chem. Theory Comput.*, 9(7):3136–3150, July 2013.
- [221] H.-J. Woo and B. Roux. Calculation of absolute protein–ligand binding free energy from computer simulations. *PNAS*, 102(19):6825–6830, Oct. 2005.
- [222] M. Wszelaka-Rylik and P. Gierycz. Isothermal titration calorimetry (ITC) study of natural cyclodextrins inclusion complexes with drugs. *J Therm Anal Calorim.*, 111(3):2029–2035, Mar. 2013.
- [223] I. W. Wyman and D. H. Macartney. Cucurbit[7]uril host–guest complexes with small polar organic guests in aqueous solution. *Organic & Biomolecular Chemistry*, 6(10):1796, 2008.
- [224] X. Xiong, Z. Chen, B. P. Cossins, Z. Xu, Q. Shao, K. Ding, W. Zhu, and J. Shi. Force fields and scoring functions for carbohydrate simulation. *Carbohydrate Research*, 401:73–81, Jan. 2015.
- [225] M. Xu, A. Unzue, J. Dong, D. Spiliopoulos, C. Nevado, and A. Caflisch. Discovery of CREBBP bromodomain inhibitors by high-throughput docking and hit optimization guided by molecular dynamics. *J. Med. Chem.*, 59(4):1340–1349, Feb. 2016.
- [226] X. Xue, Y. Zhang, Z. Liu, M. Song, , Y. Xing, Q. Xiang, Z. Wang, Z. Tu, Y. Zhou, K. Ding, and Y. Xu. Discovery of benzo[cd]indol-2(1H)ones as potent and specific BET bromodomain inhibitors: Structure-based virtual screening, optimization, and biological evaluation. *J. Med. Chem.*, 59(4):1565–1579, Jan. 2016.
- [227] Y. Yang, L. Zhao, B. Xu, L. Yang, J. Zhang, H. Zhang, and J. Zhou. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors. *Bioorganic Chemistry*, 68:236–244, Oct. 2016.
- [228] J. Yin, A. T. Fenley, N. M. Henriksen, and M. K. Gilson. Toward Improved Force-Field Accuracy through Sensitivity Analysis of Host-Guest Binding Thermodynamics. *The Journal of Physical Chemistry B*, 119(32):10145–10155, Aug. 2015.
- [229] J. Yin, N. M. Henriksen, D. R. Slochower, and M. K. Gilson. The SAMPL5 Host-Guest Challenge: Computing Binding Free Energies and Enthalpies from Explicit

- Solvent Simulations by the Attach-Pull-Release (APR) Method. *J Comput Aided Mol Des*, (31):133–145, 2017.
- [230] J. Yin, N. M. Henriksen, D. R. Slochower, M. R. Shirts, M. W. Chiu, D. L. Mobley, and M. K. Gilson. Overview of the SAMPL5 host–guest challenge: Are we doing better? *J Comput Aided Mol Des*, (31):1–19, 2017.
- [231] F. M. Ytreberg. Absolute FKBP binding affinities obtained via nonequilibrium unbinding simulations. *The Journal of Chemical Physics*, 130(16):164906, Apr. 2009.
- [232] G. Zhang, A. N. Plotnikov, E. Rusinova, T. Shen, K. Morohashi, J. Joshua, L. Zeng, S. Mujtaba, M. Ohlmeyer, and M.-M. Zhou. Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains. *J. Med. Chem.*, 56(22):9251–9264, Nov. 2013.
- [233] H. Zhang, T. Tan, and D. van der Spoel. Generalized Born and Explicit Solvent Models for Free Energy Calculations in Organic Solvents: Cyclodextrin Dimerization. *J. Chem. Theory Comput.*, 11(11):5103–5113, Nov. 2015.
- [234] H. Zhao, L. Gartenmann, J. Dong, D. Spiliotopoulos, and A. Caflisch. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. *Bioorg. Med. Chem. Lett*, 24(11):2493–2496, June 2014.